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aa amino acid
AIDS acquired immunodeficiency syndrome
ALPase alkaline phosphatase
Ang angiopoietin
AVM arteriovenous malformations
COX2 cyclooxygenase-2
cDNA complementary deoxyribonucleic acid
E embryonic day
EC endothelial cell
ECM extracellular matrix
EGF epidermal growth factor
FGF fibroblast growth factor
FIGF c-fos-induced growth factor
FVIIIRA Factor VIII related antigen
GM-CSF granulocyte-monocyte colony-stimulating factor
HEL human erythroleukaemia cell line
HEV high endothelial venule
HIF-α hypoxia-inducible transcription factor-α
HGF hepatocyte growth factor
Ig immunoglobulin
IGF-1 insulin-like growth factor-1
IL interleukin
INFγ interferon gamma;
kb kilobase
kDa kilodalton
KS Kaposi’s sarcoma
LYVE-1 lymphatic vessel endothelial hyaluronan receptor
MAPK mitogen activated protein kinase
MCP-1 membrane cofactor protein-1
MMP matrix metallo proteinases
mRNA messenger ribonucleic acid
NP-1 neuropilin-1
NO nitrix oxide
5’Nase 5’-nucleotidase
PA plasminogen activator
PAI-1 plasminogen activator inhibitor-1
PAN puromycin aminonucleoside nephrosis
PCNA proliferating cell nuclear antigen
PDGF platelet-derived growth factor
PF4 platelet factor-4
PlGF placenta growth factor
PMA phorbol myristate 12, 13-acetate
RTK receptor tyrosine kinase
RT-PCR reverse transcriptase polymerase chain reaction
SMC smooth muscle cell
tek tunica interna endothelial cell kinase
8tie tyrosine kinase with immunoglobulin and epidermal growth factor
homology domains
TIMP tissue inhibitor of metalloproteinases
TNF-α tumor necrosis factor- α
TSP-1 trombospondin-1
UEA I Ulex europaeus I lectin
VCAM vascular cell adhesion molecule-1
VEGF vascular endothelial growth factor
VEGFR VEGF receptors 1, 2, 3
VEGI vascular endothelial growth inhibitor
VM venous malformation
vWF von Willebrand factor
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ABSTRACT
Three different growth factor systems have been described acting via endothelial cell-
specific receptor tyrosine kinases (RTKs). These are vascular endothelial cell growth
factors (VEGFs), angiopoietins (Angs) and ephrins. Recent studies on endothelial
gene targeting suggest that they play a role in embryonic development and contribute
to maintaining the integrity and responses to environmental and endogenous factors in
the adult vasculature. VEGF-C, VEGF-D and VEGF receptor-3 are thought to control
lymphangiogenesis (development of lymphatic vessels). Lymphatic vessel endothelial
hyaluronan receptor (LYVE-1), podoplanin and Prox-1 are novel molecular markers
of the lymphatic endothelium. Lymphatic vessels have been difficult to study due to a
lack of appropriate molecular tools, but antibodies raised against these novel mole-
cules have offered an insight into their gene expression studies in tissues.
Here it was shown that VEGFR-3 identifies a distinct vessel population both
in fetal and adult skin, which has properties of lymphatic vessels. The expression of
VEGFR-3 was studied in normal human skin by in situ hybridization, iodinated ligand
binding, and immunohistochemistry. A subset of developing vessels expressed the
VEGFR-3 mRNA in fetal skin as shown by in situ hybridization and radioiodinated
VEGF-C bound selectively to a subset of vessels in adult skin that had morphological
characteristics of lymphatic vessels. Monoclonal antibodies against the extracellular
domain of VEGFR-3 stained specifically endothelial cells of dermal lymph vessels.
These results established the utility of anti-VEGFR-3 antibodies in the identification
of lymphovascular channels in the skin.
To define the molecular anatomy of the known endothelial growth factor receptors
in the cardiovascular system, their expression patterns were studied. Frozen sections
of human fetal heart were stained immunohistochemically with receptor-specific
monoclonal or polyclonal antibodies. The results demonstrate differential expression
of the endothelial growth factor receptors in distinct types of vessels in the human
heart. This information is useful for the understanding of their roles in physiological
and pathological processes and for their diagnostic and therapeutic application in
cardiovascular medicine.
Fenestrated capillaries of several organs including the bone marrow, splenic
and hepatic sinusoids, kidney glomeruli and endocrine glands expressed VEGFR-3.
VEGF-C and VEGF-D, which bind both VEGFR-2 and VEGFR-3 were expressed in
vascular smooth muscle cells. In addition, intense cytoplasmic staining for VEGF-C
was observed in neuroendocrine cells, such as the α-cells of the islets of Langerhans,
prolactin secreting cells of the anterior pituitary, adrenal medullary cells and
dispersed neuroendocrine cells of the gastrointestinal tract. VEGF-D was observed in
the innermost zone of the adrenal cortex and also in certain dispersed neuroendocrine
cells. These results suggest that VEGF-C and VEGF-D have a paracrine function in
blood vessels and perhaps a role in peptide release from secretory granules of certain
neuroendocrine cells to surrounding capillaries.
 Despite intensive research over the past decade, the exact lineage relationship
of Kaposi's sarcoma (KS) tumor cells has not yet been settled. The expression of two
markers for lymphatic endothelial cells (EC), i.e., VEGFR-3 and podoplanin, was in-
vestigated in AIDS and classic KS. Both markers were strongly expressed by cells
lining irregular vascular spaces in early KS lesions and by tumor cells in advanced
KS. Double-staining experiments by confocal laser microscopy established that
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VEGFR-3-positive and podoplanin-positive cell populations were identical and uni-
formly expressed CD31. By contrast, these cells were negative for CD45, CD68, and
PAL-E, excluding their hematopoietic and blood vessel endothelial cell nature. Podo-
planin expression in primary KS tumor lysates was confirmed by Western blot analy-
sis. Both splice variants of VEGFR-3 were found in KS-tumor-derived RNA by RT-
PCR. In contrast to KS tumor cells in situ, no expression of VEGFR-3 and podoplanin
was detected in any of four KS-derived spindle cell cultures and in one KS-derived
autonomously growing cell line (KS Y-1). Lack of these antigens on cultured cells
derived from KS lesions indicates loss of the in vivo phenotype of certain KS tumor
cell lines in culture.
VEGFR-3 was also studied by immunohistochemistry in benign, borderline,
and malignant vascular tumors. Although normal mesenchymal tissues showed
VEGFR-3 only in the lymphatics, benign and malignant vascular tumors and
neovascularization of nonendothelial tumors showed widespread VEGFR-3
distribution. All lymphangiomas and KSs showed consistent VEGFR-3 reactivity.
The results indicated that although VEGFR-3 shows specificity toward lymphatics in
normal tissues, this receptor is distributed extensively in benign and malignant
vascular tumors and therefore can be considered a novel marker in the assessment of
endothelial cell differentiation of vascular neoplasms.
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REVIEW OF THE LITERATURE
1. The VEGF family
1.1. GROWTH FACTORS
1.1.1. VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
Vascular endothelial growth factor (VEGF) is a highly specific mitogen for
vascular endothelial cells (Leung et al., 1989). It was originally found to be
responsible for glioma-associated brain edema because glioma cells produce it (Bruce
et al., 1987). Five human VEGF isoforms of 121, 145, 165, 189, and 206 amino acids
(VEGF121-206) are generated as a result of alternative splicing from a single VEGF
gene (Houck et al., 1991; Leung et al., 1989; Park et al., 1993; Poltorak et al., 1997;
Tischer et al., 1989). These isoforms differ in their molecular mass and biological
properties, such as their ability to bind to cell-surface heparin-sulfate proteoglycans
(Ferrara and Henzel, 1989). All VEGF isoforms can bind either of two receptor
tyrosine kinases, VEGFR-1 (or Flt-1) or VEGFR-2 (or KDR/Flk-1) (Meyer et al.,
1999) (Figure 1). Neuropilin-1 binds the VEGF164 isoform and can potentiate
VEGFR-2 activity, acting as a co-receptor (Soker et al., 1998).
Figure 1. Schematic representation of VEGFRs and their ligands. Adapted from
Ferrara 1999.
Endothelial cell
VEGFR-1 VEGFR-2 VEGFR-3
NEUROPILINVEGF121
VEGF165
VEGF-B
PlGF-1
PlGF-2 VEGF-C
VEGF-D
VEGF165
PlGF-2
VEGF-E
The expression of VEGF is potentiated in response to hypoxia (Shweiki et al.,
1992), by activated oncogenes, and by a variety of cytokines (Pages et al., 2000; Park
et al., 1993). VEGF induces endothelial cell proliferation, promotes cell migration,
13
and inhibits apoptosis (D'Arcangelo et al., 2000). In vivo VEGF induces angiogenesis
as well as permeabilization of blood vessels (Roberts and Palade, 1995), and plays a
central role in the regulation of vasculogenesis (Millauer et al., 1993).
VEGF contributes to the vascular remodelling that occurs during the ovarian cycle
and embryonic implantation (Hazzard et al., 1999; Shweiki et al., 1993) and disorders
like endometriosis (Lebovic et al., 2000; Mahnke et al., 2000). Deregulated VEGF
expression contributes to the development of solid tumors by promoting tumor
angiogenesis and to the etiology of several additional diseases that are characterized
by abnormal angiogenesis like diabetes mellitus (Hovind et al., 2000), rheumatoid
arthritis (Cho et al., 2000) and psoriasis (Bhushan et al., 1999). Consequently,
inhibition of VEGF signaling abrogates the development of a wide variety of tumors
(Kim et al., 1993; Melnyk et al., 1996; Millauer et al., 1994). In the light of novel
findings VEGF seems to act as an oncogenic factor in endothelial cells when
overexpressed (Arbiser et al., 2000).
VEGF is widely expressed in normal adult human tissues, the highest levels were
found in normal lung, kidney, heart, and adrenal gland by Northern analysis (Berse et
al., 1992). In in situ hybridization the signals were strongest in the alveolar walls of
the lung and in the renal glomeruli, in the outer cortex epithelium of the adrenal gland
and cardiac myocytes. A novel approach, in which VEGF expression was tagged with
LacZ, also provided evidence for expression of  VEGF in the endothelial cells of the
outflow tract of the heart and endocardium (Miquerol et al., 1999).
1.1.2. VEGF-B
VEGF-B has two known isoforms of 167 and 186 amino acid residues, but it has
only very low mitogenic potency (Olofsson et al., 1996; Olofsson et al., 1996). The
expression of VEGF-B is not regulated by hypoxia (Joukov et al., 1997). VEGF-B is
a ligand for VEGFR-1 and neuropilin-1 (Makinen et al., 1999; Olofsson et al., 1999).
Although originally cloned from human tumour cell libraries, it has been shown that
VEGF-B is expressed in a variety of normal human tissues, primarily in the
developing myocardium (Enholm et al., 1997; Joukov et al., 1997). In human tumors,
VEGF-B is commonly present in both benign and malignant tumors (Donnini et al.,
1999; Salven et al., 1998), although in colon neoplasms VEGF-B mRNA levels have
been found unchanged (Andre et al., 2000).
1.1.3. VEGF-C
VEGF-C was found in the growth medium of PC-3 prostatic adenocarcinoma cells
(Joukov et al., 1996; Lee et al., 1996). It is synthesized as a disulfide-linked
prepropeptide dimer of 61 kDa subunit size (Fig. 2) and by proteolytic maturation a
homodimer of 21 kDa is formed. Partially processed and mature forms of VEGF-C
bind VEGFR-3 with high affinity, while only the fully processed form binds VEGFR-
2.
VEGF-C stimulates the migration and proliferation of endothelial cells in vitro and
in vivo (Taipale et al., 1999). Recently, it was shown to stimulate the vasculogenesis
and suppress the hematopoiesis in a dose-dependent manner like VEGF-A (Hamada
et al., 2000).  Compared to VEGF, VEGF-C is 4-5 times less potent in the vascular
permeability (Miles) assay (Joukov et al., 1997). VEGF-C mRNA levels are increased
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by serum and its component growth factors, platelet-derived growth factor (PDGF)
and epidermal growth factor (EGF) as well as transforming growth factor-β (TGF-β)
and the tumor promoter phorbol myristate 12, 13-acetate (PMA) stimulation (Enholm
et al., 1997). Conversely, hypoxia, Ras oncoprotein and mutant p53 tumor suppressor
do not have an influence on VEGF-C mRNA levels. IL-1 and TNF-α have been
shown to stimulate VEGF-C expression in human lung fibroblasts and in human
umbilical vein endothelial cells (HUVEC) (Ristimaki et al., 1998). Further, the anti-
inflammatory glucocorticoid dexamethasone inhibits IL-1-induced VEGF-C mRNA
expression. It appears that VEGF-C could be a mediatior in inflammatory reactions
(Narko et al., 1999). VEGF-C has a dual biological role being able to induce both
angiogenesis and lymphangiogenesis (Oh et al, 1997; Pepper et al., 1998). The latter
has been shown by overexpressing VEGF-C in the murine skin under K14 promoter
(Jeltsch et al., 1997). Under ischemic conditions in vivo VEGF-C induces also
angiogenesis in a rabbit hindlimb model (Witzenbichler et al., 1998).
VEGF-C mRNA is weakly expressed in lymph nodes, heart, placenta, skeletal
muscle, ovary, and small intestine tissues (Joukov et al., 1996). Its mRNA levels do
not correlate with the neoplastic progression of human colonic mucosa (Andre et al.,
2000). In contrast, some evidence has been presented for VEGF-C association with
lymph node metastasis of colorectal carcinoma (Akagi et al., 2000). In breast cancer,
VEGF-C has been found in the cytoplasm of intraductal and invasive cancer cells and
its receptor in blood vessels, suggesting an angiogenic role for it (Valtola et al.,
1999).
Figure 2. Schematic model of the proteolytic processing of VEGF-C. Adapted from
Joukov, 1997.
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1.1.4. VEGF-D
Human VEGF-D was isolated as a VEGF-related transcript (Yamada et al., 1997)
and the mouse homologue, so-called c-fos-induced growth factor (FIGF) was cloned
independently (Orlandini et al., 1996). VEGF-D is a ligand for VEGFR-2 and
VEGFR-3 and a mitogen for endothelial cells (Achen et al., 1998). VEGF-D is
lymphangiogenic although less potent compared to VEGF-C see (Carmeliet, 2000).
Human VEGF-D mRNA is expressed prominently in the lung, heart and small
intestine. Two in situ analyses of both mouse fetal (E17) and young adult tissues
displayed intense VEGF-D signals in the lung (Avantaggiato et al., 1998; Farnebo et
al., 1999). On the basis of these studies VEGF-D seems to be down-regulated in the
course of development.
Table 1 A. Summary of the genetic programs for the VEGF family members as
concluded from studies in gene targeted and transgenic mice.
GROWTH
FACTOR
AFFECTED
SITE OF GENE
TARGET
PHENOTYPE REFERENCE
VEGF Replacement of the
3rd common VEGF
exon with the gene
encoding neomycin
phospho-transferase.
Dorsal aorta with a
smaller lumen.
Reduced angiogenic
sprouting.
Abnormal
development of large
thoracic blood vessels
(Carmeliet et al.,
1996)
VEGF Coding sequence of
VEGF exon replaced
by a neomycin
resistance.
Heterozygous
deletion is lethal.
Impaired blood-island
formation. Severe
anomalies (forelimb
buds, heart, cranial
region).
(Ferrara et al.,
1996)
VEGF Removal of exons 6
and 7, encoding
basic domains that
are only present in
VEGF164 and/or
VEGF188.
Impaired myocardial
angiogenesis.
Ischemic cardio-
myopathy.
(Carmeliet et al.,
1999)
VEGF
(Conditional)
Cre-loxP-mediated
gene ablation after
administration of
interferon-α
Impaired postnatal
vascular development
and endothelial
survival.
(Gerber et al.,
1999)
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Table 1B. Summary of the genetic programs for the VEGF family members as con-
cluded from studies in gene targeted and transgenic mice.
GROWTH
FACTOR
AFFECTED
SITE OF GENE
TARGET
PHENOTYPE REFERENCE
VEGF Insertion of an IRES-
LacZ reporter cassette
into the 3’ untranslated
region of the gene
(Miquerol et al.,
1999)
VEGF-B Replacement of exons 3-
7 with a promoter-less β-
geo cassette
Smaller hearts.
Dysfunctional
coronary
vasculature
(Bellomo et al.,
2000)
VEGF Expression of murine
VEGF164 cDNA under
the keratin 14 promoter
expression cassette
Skin:more
numerous,
enlarged, tortorous,
leaky vessels
(Detmar et al.,
1998)
VEGF-C Expression of VEGF-C
cDNA under the human
keratin 14 promoter
Skin: hyperplastic
lymphatic vessels
(Jeltsch et al.,
1997)
 1.1.5. VEGF-E
Orf virus is a linear double-stranded DNA virus that causes contagious pustular
dermatitis which is characterized histologically by vascular and edematous lesions
(Ogawa et al., 1998). As the virus was only found in the keratinocytes and the vascu-
lar response in the dermis was VEGF-like, the observations led to the discovery of
VEGF-E from the genome of Orf virus strain NZ-7. VEGF-E induces tissue-factor
(TF) expression, the proliferation, migration and sprouting of cultured vascular en-
dothelial cells and angiogenesis in vivo (Meyer et al., 1999).
1.2. The VEGF receptors
1.2.1. VEGFR-1
VEGFR-1 receptor is expressed predominantly in endothelial cells but it is found
in trophoblast cells, monocytes(Barleon et al., 1996) and renal mesangial cells
(Takahashi et al., 1995). In addition, there are tumorigenic cell types that express
VEGFR-1 (Cohen et al., 1995). The receptor is probably activated by all VEGF iso-
forms but fulfills somewhat different functions in vivo, as targeted gene disruption
experiments revealed (Shalaby et al., 1995). VEGFR-1 can transduce signals of other
growth factors belonging to the VEGF family, but only the VEGF isoforms can bind
to VEGFR-1. The transcription of VEGFR-1 is enhanced by hypoxia (Gerber et al.,
1997). Alanine-scanning mutagenesis has revealed that Asp (63), Glu (64), and Glu
(64) and Glu (67) are required for the binding of VEGF to VEGFR-1. VEGFR-1 does
not induce cell proliferation in response to VEGF. MAP kinase is not activated by
VEGF in cells expressing recombinant VEGFR-1 (Seetharam et al., 1995). Therefore
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it is possible that VEGFR-1 does not induce cell proliferation, because it does not ac-
tivate MAP kinase. Finally, activation of VEGFR-1 results in the generation of prote-
ases that are required for the breakdown of the basement membrane of blood vessels
in the first steps of angiogenesis (Olofsson et al., 1998; Unemori et al., 1992).
1.2.2. VEGFR-2
VEGFR-2 is also expressed predominantly in endothelial cells, but also in hema-
topoietic stem cells, megakaryocytes, and retinal progenitor cells (Katoh et al., 1995).
In the retina, two functional VEGFR-2 forms are expressed as a result alternative
splicing (Wen et al., 1998). Malignant melanoma cells express VEGFR-2. Only the
final glycosylated form of VEGFR-2 is capable of undergoing autophosphorylation in
response to VEGF (Takahashi and Shibuya, 1997). Transcription of VEGFR-2 is not
enhanced by hypoxia. VEGFR-2 production is also up regulated under hypoxic con-
ditions, but the mechanism responsible for the induction seems to be post-
transcriptional (Waltenberger et al., 1996). Activation of the VEGFR-2 receptor by
VEGF in cells devoid of VEGFR-1 results in a mitogenic response (Kondo et al.,
1998). When VEGFR-2 is activated by VEGF, endothelial cells migration is obtained
(Yoshida et al., 1996).
1.2.3. NEUROPILIN-1
Endothelial cells were also found to contain VEGF receptors possessing a lower
molecular weight than either VEGFR-2 or VEGFR-1 (Gitay-Goren et al., 1992). It
was subsequently found that these smaller VEGF receptors bind to VEGF165 but, but
not to VEGF121. Therefore these receptors are not related to the VEGFR-1 or
VEGFR-2 that bind both VEGF isoforms (Gitay-Goren et al., 1996), but instead
neuropilin-1, a receptor for several types of semaphorins that were initially
characterized as repellents of nerve growth cones (He and Tessier-Lavigne, 1997;
Soker et al., 1998). Neuropilin-1 also functions as a receptor for the heparin binding
form of PlGF, PlGF-2, but not for PlGF-1 (Migdal et al., 1998). The neuropilins have
a short intracellular domain and thus are unlikely to function as independent
receptors. On the other hand, gene distruption studies indicate that mouse embryos
lacking a functional neuropilin-1 gene die because their cardiovascular system fails to
develop properly (Kitsukawa et al., 1997).
Neuropilin-1 is considered a VEGF165 co-receptor, because VEGFR-2 has been
shown to bind VEGF165 more efficiently in cells expressing neuropilin-1. In addition,
neuropilin potentiates effect endothelial cell migratory response to VEGF165.
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Table 2. Biological functions of VEGFRs during development concluded from gene
targeting experiments.
VEGF
RECEPTOR
SITE OF GENE
TARGET
PHENOTYPE REFERENCE
VEGFR-1 The translated portion
of the 1st coding exon
replaced with LacZ
Disorganized
vasculature in early
embryos
(Fong et al., 1995)
VEGFR-1 As  above. Increase in the
number of
endothelial cell
progenitors
(Fong et al., 1999)
VEGFR-2 LacZ into the first exon Absence of yolk-sac
blood islands
No organized blood
vessels in the
embryo or yolk sac
Severely reduced
hematopoietic
progenitors
(Shalaby et al.,
1995)
Neuropilin-1 Overexpression of NP-
1 in ES cells
Excess capillaries
and blood vessels
Abnormal heart
Ectopic sprouting
and defasciculation
of nerve fibers
(Kitsukawa et al.,
1995)
Neuropilin-1 Sequence encoding the
N-terminal half of the
alpha1 domain targeted
with neomycin
resistance gene (neo)
Agenesis of
branchial arch, great
vessels and dorsal
aorta
Transposition of the
aortic arch
Insufficient septation
of the truncus
arterious.
Disorganized
extraembryonic
vasculature
(Kitsukawa et al.,
1997)
VEGFR-3 LacZ in the 1st coding
exon
Abnormally
organized large
vessels with
defective lumen.
Severe anemia.
(Dumont et al. ,
1998)
(Hamada et al. ,
2000)
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1.2.4. VEGFR-3
VEGFR-3 is a highly glycosylated, relatively stable, cell surface associated
tyrosine kinase of approximately 180 kDa. Its cDNA was cloned from human
erythroleukemia cell and placental libraries (Aprelikova et al., 1992; Galland et al.,
1993). On the basis of structural similarities VEGFR-1-3 receptors constitute a
subfamily of class III tyrosine kinases. Two isoforms of VEGFR-3, have been
identified differing in their C-terminal ends.
In the early stages of development VEGFR-3 is widely expressed in the vascular
endothelial cells (Kukk et al., 1997). Disruption of the VEGFR-3 gene causes disor-
ganization in the large vessels, resulting in defective lumina. As a result, the pericar-
dial cavity is filled with fluid, and the embryo dies of cardiovascular failure (Dumont
et al., 1998). Further studies with this knockout model have shown that the embryos
suffer from severe anemia (Hamada et al., 2000). After organogenesis, the VEGFR-3
becomes restricted to lymphatic endothelial cells (Kaipainen et al., 1993) and a mis-
sense mutation in VEGFR-3 which creates an inactive tyrosine kinase causes primary
human lymphedema (Irrthum et al., 2000; Karkkainen et al., 2000). In the neovascu-
lature of tumors VEGFR-3 is upregulated, which limits the use of the receptor in de-
fining lymphatic vessels (Valtola et al., 1999). Recently, it has been shown that inac-
tivation of VEGFR-3 by blocking it with a monoclonal antibody suppresses tumor
growth by inhibiting the neoangiogenesis of tumor-bearing tissues (Kubo et al.,
2000). In the light of the findings, VEGFR-3 may be needed for maintaining the in-
tegrity of the endothelial lining during angiogenesis.
2. The Angiopoietin/Tie- family
2.1. GROWTH FACTORS
2.1.1 Angiopoietin-1
Ang-1 is a 70-kDa secreted glycoprotein that induces the phosporylation of the
Tie-2 receptor (Davis et al., 1996). It is not mitogenic for endothelial cells in culture,
does not it induce tube formation within a collagen substrate, nor cause neovasculari-
zation in the corneal micropocket assay (Asahara et al., 1998; Maisonpierre et al.,
1997). When Ang-1 was added together with VEGF in the same assay, the effect was,
however additive. Ang-1 inhibits apoptosis in endothelial cells dose-dependently
during a serum deprivation and this anti-apoptotic effect is increased if VEGF is
added (Kwak et al., 1999). Recently it was found that the mechanism by which Ang-1
inhibits EC permeability is through the regulation of junctional complexes, PECAM-1
and VE cadherin (Gamble et al., 2000). After vasculogenesis, the expression pattern
of Ang-1 broadens from the myocardial lining of the endocardium to the periendothe-
lial mesenchymal cells as the rest of the vasculature matures. Ang-1 overexpression
under the K14-promotor inhibits inflammatory agent [mustard oil, serotonin and
platelet activating factor (PAF)] induced permeability (Thurston et al., 1999).
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2.1.2. Angiopoietin-2
Ang-2 acts as a Tie-2 receptor blocker on endothelial cells (Maisonpierre et
al., 1997). Indeed angiopoietins were the first vertebrate example of a growth factor
family consisting of both activatory and inhibitory ligands. In adults, Ang-2 is ex-
pressed primaly at sites of vascular remodelling, where it is thought to block the con-
stitutive stabilizing action of Ang-1. Gene targeting studies suggest that Ang-2 par-
ticipates in lymphatic development see (Carmeliet, 2000).
2.1.3. Angiopoietin-3 and Angiopoietin-4
Human Ang-3 and mouse Ang-4 are structurally more divergent from each
other than are the mouse and human versions of angiopoietin-1 and angiopoietin-2
(Nishimura et al., 1999). Angiopoietin-3 and angiopoietin-4 have very different dis-
tributions in their respective species, and ang-4 appears to function as an agonist.
Ang-3 cDNA was cloned from a human aorta cDNA library. It is a 503 amino acid
protein having 45.1% and 44.7% identity with human angiopoietin-1 and human an-
giopoietin-2, respectively (Nishimura et al., 1999). Additionally, Ang-3 is a secreted
protein, but is not a mitogen in endothelial cells. Its mRNA is expressed in the lung
and cultured HUVECs (Nishimura et al., 1999). VEGF decreased Ang-3 mRNA ex-
pression in HUVECs slightly suggesting that the regulation of Ang-3 mRNA expres-
sion differs from that of Ang-2. The NH2-terminal and COOH-terminal portions of
Ang-3 contain the characteristic coiled-coil domain and fibrinogen-like domain that
are conserved in other known Angs. Ang-3 has the highly hydrophobic region at the
N-terminus (approximately 21 amino acids) that is typical of a signal sequence for
protein secretion (Kim et al., 1999). According to the Northern analysis Ang-3
mRNA is most abundant in the adrenal glands, placenta, thyroid gland, heart and
small intestine in human adult tissues. The biological properties of Ang-3 are at pre-
sent unknown. According to the Northern analysis, the highest expression of Ang-4 is
exhibited to lung.
2.2. The Tie receptors
2.2.1. Tyrosine kinase with immunoglobulin and EGF homology domains (Tie-1)
Tie-1 is a member of a subfamily of endothelial cell RTKs whose extracellular
domains contain three different types of structural motifs: immunoglobulin (Ig)-like
loops, cysteine-rich epidermal growth factor (EGF)-like domains and fibronectin type
III (FN III) domains (Iwama et al., 1993; Maisonpierre et al., 1993; Partanen et al.,
1992; Partanen and Dumont, 1999; Sato et al., 1993). Tie-1 is an orphan receptor, the
expression of which is thought to be restricted to endothelial cells and early hema-
topoietic cells of myeloid differentiation (Armstrong et al., 1993; Batard et al., 1996;
Bredoux et al., 1997; Hashiyama et al., 1996; Iwama et al., 1993; Korhonen et al.,
1994; Kukk et al., 1997; Partanen et al., 1992; Sato et al., 1993; Suda et al., 1997;
Yano et al., 1997). Vasculogenesis happens succesfully without Tie-1 as shown by
gene disruption studies (Puri et al., 1995). However, the receptor is crucial for main-
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taining the vascular integrity and survival of endothelial cells (Partanen et al., 1996;
Sato et al., 1995).
2.2.2. Tie-2 or Tunica interna endothelial cell kinase (Tek)
Tie-2 is a receptor tyrosine kinase which is expressed by the vascular endothelium
and primitive hemopoietic cells (Sato et al., 1998) and anti-Tie-2 antibody has proved
to be useful in purification of hematopoietic stem cells in the fetal liver (Hsu et al.,
2000). As already mentioned, angiopoietins 1-4, have been identified to bind to Tie-2
(Davis et al., 1996; Maisonpierre et al., 1997). Tie-2 is upregulated during the later
stages of angiogenesis (maturating wound, ovarian cycle) and is widely expressed and
tyrosine phosphorylated in the vascular endothelium of quiescent adult tissues
(Asahara et al., 1998). An activating mutation in Tie-2 has shown to cause inherited
venous malformations in humans (Vikkula et al., 1996). The Tie-2 signaling pathway
may regulate endothelial cell recruitment of the stromal cells required to encase and
thereby stabilize endothelial tubes.
3. The Ephrin/Eph Family
The ephrins exist in two classes: GPI-linked [class A(1-8)] or transmembrane
[class B(1-6)] proteins (Holder and Klein, 1999).  Fourteen genes have been described
that are related to Eph by their sequences and by the general characteristics of their
kinase and extracellular domains. During embryogenesis Eph signaling contributes to
segmentation, axon quidance and fasciculation; and in addition it is also involved in
controlling cell migration, development of the vascular system and probably in cellu-
lar transformation. At least eight Eph receptor ligands (A1-5 and B 1-3) have been
described; they do not function as typical soluble ligands, but must be membrane at-
tached to activate their receptors (Davis et al., 1994; Gale and Yancopoulos, 1997).
 When EphrinA1 binds to its receptor, EphA2 on HUVECs it promotes the cell
migration but not proliferation (Pandey et al., 1995). The embryonic vasculature of
ephrin EphrinB2-deficient mice is severely disrupted, due to a lack of remodeling of
the primary capillary network (Wang et al., 1998). Interestingly, ephrinB2 is exclu-
sively expressed in embryonic arteries while EphB4 shows complementary expression
in veins. Ephrin-B2/EphB4 expression studies suggest that molecular differences are
at least in part genetically programmed genetically in arterial versus venous endothe-
lia, and that these differences may be critical to the normal development of the vas-
culature (Gale and Yancopoulos, 1999).
4. Other endothelial cell markers
The vascular endothelium has a very different antigenic profile depending on the
type of vessel and the tissue in which it lies. Such findings are not unexpected, con-
sidering the differing function of endothelial cells in different tissues, such as the
maintenance of the blood-brain barrier, hormonal transport in endocrine capillaries
(adrenal, thyroid), renal glomeruli and the high endothelial venules of the lymph
nodes and spleen. Traditionally patologists have used anti-von Willebrand factor,
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anti-CD31, anti-CD34, anti-laminin, anti-type IV collagen etc. antibodies to distin-
guish vascular structures.
A new era in pathology has begun, with the aid of new molecular techniques, such
as serial analysis of gene expression (SAGE) and cDNA microarrays. These have
enabled the measurement of the expression of thousands of genes in a single
experiment, revealing many new, potentially important cancer genes (Kononen et al.,
1998). Instead of using immunohistochemical staining with only one antibody, it is
already possible to analyse the profiles of tens or hundreds of antigens on endothelial
cells (St. Croix et al., 2000).
As a result of comparing human tumor and normal endothelia using a modification
of the SAGE technique, some important conclusions have already been drawn, normal
and tumor endothelia seem to be highly related, and share many endothelial cell-
specific markers. Secondly, the tumor derived endothelium is qualitatively different
from the same type of normal endothelium. The tumor endothelium is generally
different from the endothelium in the surrounding normal tissue. Interestingly, most
of the genes expressed differentially in tumor endothelia are also expressed during
angiogenesis during corpus luteum formation and wound healing (St. Croix et al.,
2000).
In the following, established and new antigenic markers of differentiated
endothelia are shortly summarized.
4.1. Von Willebrand factor
Von Willebrand Factor (vWF) or Factor VIII related antigen (FVIIIRA) is a mul-
timer produced by endothelial cells and megakaryocytes, it is stored in intracellular
organelles, such as the Weibel-Palade bodies and α-granules in endothelial cells and
platelets (Spadafora-Ferreira et al., 2000). VWF also plays an important role in plate-
let aggregation and adhesion to the cell walls of injured vessels (Kuzu et al., 1992).
The maturation status of the cell might explain the variability in vWF expression
(Bohling et al., 1983; Enzinger and Weiss, ; Zhu and Gu, 1988). In most tissues cap-
illaries and sinuses do not stain for vWF whereas in the large vessels, arteries and
veins the staining is very strong (Kuzu et al., 1992). Lymphatic vessels stain for vWF
weakly (Marchetti, 1996).
4.2. CD31
CD31 or platelet-endothelial cell adhesion molecule (PECAM)-1 is a 130-kDa gly-
coprotein commonly used as an endothelium-specific marker (Ilan et al., 2000). Its
expression starts early in development and persists through adulthood. Antibodies di-
rected against PECAM-1 have been shown to affect angiogenesis, endothelial cell
migration, and polymorphonuclear leukocyte transmigration (Mahooti et al., 2000).
PECAM-1 functions as an adhesion and signaling molecule between adjacent endo-
thelial cells and between endothelial cells and circulating blood elements. Generally,
CD31 is strongly expressed in all endothelial cells including capillaries, sinuses and
larger vessels. Hepatic sinuses and splenic sinusoids are weakly labeled (Kuzu et al.,
1992).
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4.3. CD34
CD34 is a 110kDa heavily glycosylated transmembrane protein. It is present on
immature hematopoietic precursor cells and a ligand for I-selectin involved in leuco-
cyte traffic from blood to a lymph node or sites of inflammation (van de Rijn and
Rouse, 1994). Generally, the endothelial staining intensity is not strong and back-
ground staining of connective tissue and basement membranes may cause confusion
(Kuzu et al., 1992). Splenic sinuses do not stain and further, the sinuses in the liver
and lymph node show weak but definitive positivity (Natkunam et al., 2000).
4.4. Ulex europaeus I lectin
Ulex europaeus I lectin (UEA-I) is specific for alpha-L-fucose-containing glyco-
conjugates (Gomez et al., 1995). UEA-I is a more sensitive marker for endothelial
cells than vWF (Holthofer et al., 1982). UEA-I also stains many neoplastic cells from
endothelial sarcomas (Miettinen et al., 1983) and it can also detect sinusoidal endo-
thelial cells from the human liver (Petrovic et al., 1989).
4.5. Molecular markers of the lymphatic system vs blood vasculature
According to previously published papers, the lymphatic endothelium can be char-
acterized by using 5’-Nucleotidase (Nase)-alkaline phosphatase (ALPase) double
staining (Kato, 1990). The lymphatic endothelium is marked by strong 5’-Nase activ-
ity that is significantly lower or absent in blood vessels whereas the blood vessels
stain for ALPase. Other possibilities for distinguishing between lymphatic capillaries
and blood capillaries are toluidine blue staining following arterial perfusion-fixation
and staining of basement membrane components, like laminin, collagen IV (Kubo et
al., 1990; Otsuki et al., 1990).
PAL-E is a monoclonal antibody (IgG2a) that stains the endothelium of capillaries,
medium-sized and small veins, and venules in frozen sections (Schlingemann et al.,
1985). Unfortunatelly, it reacts weakly, or not at all to the endothelia of large,
medium-sized, and small arteries, arterioles, and large veins and does not stain the
endothelial lining of lymphatic vessels and sinus histiocytes. CD31/PAL-E double
staining has been used in the detection of lymphatic vessels (de Waal et al., 1997).
4.6. Proposed new lymphatic endothelial markers
4.6.1. Lymphatic vessel endothelial hyaluronan receptor (LYVE-1)
LYVE-1 was found as a result of a homology search of the combined Human Ge-
nome databases with the amino acid sequence of full-length CD44 antigen sequence
(Banerji et al., 1999). LYVE-1 is thus a homologue of the CD44 glycoprotein, but it
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is expressed mostly on lymphatic endothelia, where CD44 is almost lacking. Other
expressing cells include sinusoidal cells, adrenal zona reticularis cells, pancreatic
exocrine cells, syncytiotrophoblasts, cerebral cortex neurons and kidney tubular
cuboidal epithelium. The function of LYVE-1 is not known. LYVE-1 displays exqui-
site specificity for binding hyaluronan which the major component of the extracellular
matrix (ECM) (Toole, 1997). Hyaluronan is a key factor involved in cellular migra-
tion and adherence and it is expressed nearly everywhere in the body where high
swelling capacity is provided. CD44 and LYVE-1, and hyaluronan receptor for endo-
cytosis (HARE) constitute plasma membrane receptors for hyaluronan. Critical data
on LYVE-1 expression in vascular tumors and tumor neovasculature is lacking, even
though the production of polyclonal anti-LYVE-1 antibodies has been achieved.
4.6.2. Prox-1
The homeobox gene Prox-1 was originally cloned by homology to the Drosophila
melanogaster gene prospero (Oliver et al., 1993). Prox-1 is expressed in a sub-
population of endothelial cells which by budding and sprouting, give rise to the lym-
phatic system (Wigle et al., 1999). Prox-1-deficient homozygous mice have unaf-
fected vasculogenesis and angiogenesis, but liver and lymphatics do not develop
(Wigle and Oliver, 1999).  Human Prox-1 gene has been mapped to chromosome
1q32.2-q32.3, and its product shows 94% similarity to the chicken protein (Zinovieva
et al., 1996). The conserved structure and expression pattern of the Prox-1 gene imply
that it may play the same roles in humans as in other vertebrates. The human Prox-1
gene is most actively expressed in the developing lens. Anti-Prox-1 antibodies pro-
vide a highly specific marker of lymphatic endothelial cells as shown in the CAM as-
say (Papoutsi et al., 2000).
4.6.3. Podoplanin
A 43-kd membrane protein called podoplanin was identified when glomerular
membrane proteins of normal and puromycin aminonucleoside nephrosis (PAN) rats
were compared (Breiteneder-Geleff et al., 1997). Glomerular visceral epithelial cell or
podocyte foot processes, flatten in human minimal change nephropathy, causing se-
vere proteinuria. PAN provides a model of human minimal change nephropathy.
Affinity-purified rabbit anti-podoplanin were shown to mark lymphatic capillary
endothelium. Other cell types positive for the antibody include podocytes, the parietal
epithelial cells of Bowman’s capsule, the luminal cell membranes of type I alveolar
epithelial cells, pleural mesothelial cells, osteocytes, osteoblasts, thymic epithelial
cells. Staining positivity was also found in the plexus choroideus, leptomeninges,
bone tissue, marginal sinuses of lymph nodes and the mesothelium of spleen, liver,
stomach, and intestine.
   A panel of vascular tumors was studied with anti-podoplanin and anti-
VEGFR-3 antibodies and the results showed overlapping patterns for these two
markers (Breiteneder-Geleff et al., 1999). Podoplanin protein was not present in
capillary, cavernous or venous hemangiomas whereas it could be detected from
lymphangioma, angiosarcoma (variation 0-70%) and KS. A rare intrapericardial
lymphangioma has been analyzed with anti-podoplanin antibody and found it suitable
for a lymphatic marker (Sinzelle et al., 2000). No data on podoplanin expression in
tumor neovasculature is available. Expression of podoplanin was found to correlate
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with the caliber of lymphatic vessels and be prominent in capillaries while larger
lymphatic vessels with smooth muscle cells may lack it.
5. Vasculature
In order to understand the molecular markers that allow the differentiation of blood
and lymphatic vessels, one has to understand their functions and the development that
leads to the differentiated vessels. In the processes called vasculogenesis and angio-
genesis.
Endothelial cells line vessels in every organ and regulate the flow of nutrient
substances, diverse biologically active molecules, and the blood cells themselves.
This gate-keeping role is effected through the presence of membrane-bound receptors
for numerous molecules including proteins, lipid transporting particles, metabolites
and hormones. There are also specific junction proteins and receptors, which govern
cell-cell and cell-matrix interactions. Such proteins differ greatly in different parts of
the vasculature as a result of the developmental processes that lead to their generation.
5.1. Development
The de novo organization of endothelial cells into vessels in the absence of any
pre-existing vascular system is referred to as VASCULOGENESIS and only occurs in
the early embryo. ANGIOGENESIS, the continued expansion of the vascular tree as a
result of endothelial cell sprouting from existing vessels, occurs in avascular regions
of the embryo and is repeated many times in the mature animal, most commonly
during wound healing and tumor metastasis (Carmeliet and Collen, 1998; Hanahan
and Folkman, 1996).
 Vasculogenesis takes place during embryogenesis in the blood islands of the
yolk sac (pictured), and in the embryo through expression of growth factors, in
particular FGF and vascular endothelial growth factor (VEGF). The tyrosine receptor
kinases, VEGFR-1 and VEGFR-2, are expressed on mesenchymal cells and newly
formed ECs, respectively, are essential for the generation and proliferation of new
ECs and the formation of tubal EC structures. Angiogenesis, the continued expansion
of the vascular tree, is mediated through the expression of additional tyrosine kinase
receptors, Tie-2, which binds to angiopoietins 1-2, resulting in the maintenance of
mature vessels, the development of new vessels, and the regression of formed vessels
in processes dependent on a combination of factors, most notably on the presence or
absence of growth factors. Putative EC progenitors or angioblasts have been isolated
from adult peripheral blood (Asahara et al., 1997) and further these cells have been
shown to contribute in vasculogenesis both in physiological and pathological
conditions (Asahara et al., 1999).
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Figure 3. The formation of new vessels during vasculogenesis and angiogene-
sis.Adapted from Cines, 1998.
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Table 3. A list of known stimulators and inhibitors that contribute to different
stages of vascular development. Adapted from Carmeliet, 2000.
STAGE STIMULATORS INHIBITORS
VASCULOGENESIS VEGF, GM-CSF, bFGF,
IGF-1
?
ANGIOGENESIS VEGF, VEGF-B, VEGF-C,
VEGF-D, PlGF, VEGFR-1,
VEGFR-2, VEGFR-3, Ang-
1, Ang-2, Tie-2, FGF,
PDGF, IGF-1, HGF,
TNFα, TFGβ1,  αϖβ3,α5β
3, PA, MMP, PECAM, VE-
cadh., NO, CXC, HIF-1α,
COX2, IL-8
TSP-1, TSP-2, Endostatin,
Angiostatin, Vasostatin,
PF4, INFγ, INFβ, IL-4, Id1,
Id3, Meth, TFPI, VEGI,
TIMP, PEX, IP-10, sNP-1
ARTERIOGENESIS MCP-1, VCAM,  GM-CSF,
PA, FGF-4, MMP,  FGFR1,
Selectin, PDGF-B, TGF-β1
PAI-I, TIMP
Abbreviations: GM-CSF, granulocyte-monocyte colony-stimulating factor; IGF-1,
insulin-like growth factor-1; HGF, hepatocyte growth factor; MMP, matrix metallo
proteinase(s); NO, nitrix oxide; PA, plasminogen activator; HIF-α, hypoxia-inducible
transcription factor; MCP-1, membrane cofactor protein-1; VCAM,  vascular cell
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adhesion molecule-1; TSP, trombospondin; PF4, platelet factor 4; INFγ, interferon
gamma; Meth., metallospondin; VEGI, vascular endothelial growth inhibitor; PEX,
MMP-2 hemopexin domain TIMP, tissue inhibitor of metalloproteinases, PAI-I, plas-
minogen activator inhibitor-1.
5.2. Arteries and veins
As mentioned previously (see The Eph family), arterial and venous endothelial
cells already show molecular differences even when the embryonic vasculature ap-
pears to be a uniform plexus of interconnected tubules. Later these cells can be distin-
guished by differential lectin staining (Thurston et al., 1996).
 5.3. Lymphatic vessels
Like developing blood vessels, the first lymphatics consist only of endothelial
cells. The origin of lymphatic endothelial cells is not yet known. Could they be de-
rived from lymphangioblasts of the early mesenchyme (Huntington, 1908), from
veins by sprouting (Ranvier, 1895; Sabin, 1909), or by both mechanisms (van der
Jagt, 1932)? If lymphatic endothelial cells are derived from veins, and grow exclu-
sively by sprouting, then the main difference between angiogenesis and lymphangio-
genesis is the absence of a lymphangioblastic cell lineage. The fact is that lymphatics
develop much later than blood vessels. In humans, lymph sacs have been found in 6-
to 7-week-old embryos of 10-14 mm total lenght (van der Putte, 1975). This is nearly
one month after the development of the first blood vessels. Presumably, there are also
endothelial-lined clefts that become integrated into the growing lymphatic system, in
addition to lymphatics originating from the veins (Kampmeier, 1912; Rusznyák et al.,
1969). Much of the lymphatic system is derived from eight endothelial-lined lymph
sacs, which are located immediatelly adjacent to the veins. The jugular (an extension
of the jugular lymph sac), subclavian and posterior lymph sacs are paired and single
ones are the cisterna chyli and retroperitoneal (mesenterial) lymph sac. With excep-
tion of the cisterna chyli, the lymph sacs become transformed into primary lymph
nodes.
5.4. Endothelial cell heterogeneity and lymphocyte traffic
The trafficking, extravasation, and retention of lymphocytes within certain tissues
(e.g., lymph nodes) is mediated by several classes of specialized adhesion glycopro-
teins that are expressed on the surface of unique endothelial cells (high endothelial
venules [HEVs]) that exist in both the blood and lymph microvessels (Roitt et al.,
1996). The binding of these endothelial cell adhesion molecules to their correspond-
ing ligands on lymphocytes (L-selectin, [alpha]4[beta]7, [alpha]4[beta]1, leukocyte
function– associated antigen-1 [LFA-1], and CLA-1) tightly controls the kinetics and
magnitude of lymphocyte margination, rolling, adhesion, and extravasation, thereby
allowing these leukocytes to fulfill their immune surveillance functions and, in some
tissues, mature into fully differentiated cells (Springer, 1994). To migrate to the ex-
travascular areas, circulating leukocytes have to acquire strong adhesion interactions
to the vessel wall while resisting to continuous sheer forces. The traffic and tissue lo-
calization of leukocytes is regulated by a series of cell surface adhesion molecules
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(CAMs) that recognize specific ligands on endothelial cells and in the extracellular
matrix. The most known are the selectins, the super family of the immunoglobulins,
the integrins and the proteoglycans, that act in a cascading manner.
Stimulation of resting endothelial cells leads to the situation-specific expression of
endothelial cell molecules, which are characteristic for the activated phenotype
Likewise, trans-differentiation of endothelial cells characterizes the process through
which a specific constitutive endothelial cell phenotype is altered in response to
changes in the microenvironmental milieu that controls a specific constitutive
phenotype.
Figure 4. Endothelial cell differentiation.
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The heterogeneity of endothelial cell phenotype associated with the different types
of vessels could give important cues also to the origin of vascular neoplasms or to the
characteristics and targets of tumor of  vasculature. It is therefore important to know
what happens to these properties of endothelial cells in various disease processes.
 5.5. Disorders associated with the vasculature
       5.5.1. Vascular malformations
Vascular malformations are congenital lesions that are differentiated from heman-
giomas on the basis of their normal endothelial cell turnover and lack of excessive
proliferation. They are structural anomalies of the vascular system and may be com-
posed of capillaries, veins, lymphatics, arteries, or combinations of the above (Garzon
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et al., 2000; Mulliken and Young, 1988; Mulliken and Glowacki, 1982). However, an
association between vascular tumors and vascular malformations has been shown.
As previously mentioned, receptor specific evidence of Tie-2 mutations in fa-
miliar venous malformations or VEGFR-3 mutation in lymphatic vessel hypoplasia
indicates that abnormalities in vasculogenesis are commonly involved in the patho-
genesis of vascular malformations. Although the exact mechanism for hemangioma
development remains unknown, vascular growth factors seem to play a role in its
pathogenesis. EC proliferation in this tumor most likely results from an imbalance
between positive and negative angiogenic factors expressed by the hemangioma and
the adjacent normal tissue (table 3) (Bielenberg et al., 1999).
It has been shown that proliferation markers [proliferating cell nuclear antigen
(PCNA), VEGF, bFGF, type IV collagenase and urokinase] can distinguish
hemangiomas and vascular tumors (Takahashi et al., 1994). Table 4 lists such
neoplasms. Unlike normal adult vascular tissue within the cerebral circulation, arte-
riovenous malformations (AVMs) were shown to stain for VEGF (Rothbart et al.,
1996). Otherwise comparative immunohistochemical data on vascular malformation
versus vascular tumors is scant.
Table 4. Congenital vascular neoplasms and associated conditions.
Hemangiomas
                Complicated locations
                   Cervicofacial
                   Periorbital
                   Lumbosacral
                   Parotid
Associated syndromes
               Diffuse neonatal hemangiomatosis
               PHACES syndrome
Vascular neoplasms associated with the Kasabach-Merritt syndrome
               Kaposiform hemangioendothelioma
               Tufted angioma
Abbreviations: PHACES, Posterior fossa malformations, most commonly of the
Dandy-Walker variant; Hemangiomas (especially large, plaquelike, facial lesions);
Arterial anomalies; Cardiac anomalies and coarctation of the aorta; Eye
abnormalities; and Sternal cleft and/or supra-umbilical raphe.
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5.5.2. Vascular tumors
Vascular tumors consist of broad morphological spectrum from hamartomas to
malignant neoplasia (Mentzel et al., 1994). Tables 5 and 6 summarize the vascular
tumors of the skin and soft tissues. Knowledge about their molecular characteristics is
mostly unknown probably, because they are rare (see Tables 7 and 8). Exceptions
comprise hemangioma, lymphangioma, KS and angiosarcoma.
Table 5. Classification of vascular tumors of the skin and soft tissues according to
C.D.M. Fletcher, 1994.
I BENIGN TUMORS AND TUMOR-LIKE CONDITIONS OF BLOOD
VESSELS
    1. REACTIVE VASCULAR PROLIFERATIONS
- Papillary endothelial hyperplasia (Masson’s tumour)
- Reactive angioendotheliomatosis
- Glomeruloid hemangioma
- Bacillary angiomatosis
2. VASCULAR ECTASIAS
- Naevus flammeus
- Naevus araneus
- Venous lake
- Angioma serpiginosum
- Hereditary hemorrhagic teleangiectasia
- Angiokeratoma
3. CAPILLARY HAEMANGIOMA
- Strewberry naevus
- Tufted hemangioma
- Verrucous haemangioma
- Cherry angioma
- Lobular haemangioma (Pyogenic granuloma)
4. CAVERNOUS HAEMANGIOMA
- Ordinary cavernous haemangioma
- Sinusoidal haemangioma
5.  ARTERIOVENOUS HAEMANGIOMA
- Superficial variant (Cirsoid aneurysm)
- Deep variant
6.   MICROVENULAR HAEMANGIOMA
7.   TARGETOID HAEMOSIDEROTIC HAEMANGIOMA (“HOBNAIL
HAEMANGIOMA”
8.   EPITHELOID HAEMANGIOMA (ANGIOLYMPHOID
HYPERPLASIA WITH EOSINOPHILIA)
9.   KIMURA’S DISEASE
10. DEEP HAEMANGIOMA
- Intramuscular (diffuse and circumscribed variant)
- Synovial
- Neural
- Nodal
11. SPINDLE CELL HAEMANGIOMA
12. ANGIOMATOSIS
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Table 5. Classification of vascular tumors of the skin and soft tissues according to
C.D.M. Fletcher, 1994.
II LOW GRADE MALIGNANT VASCULAR TUMORS
1. EPITHELOID HAEMANGIOENDOTHELIOMA
2. RETIFORM HAEMANGIOENDOTHELIOMA
3. MALIGNANT ENDOVASCULAR PAPILLARY
ANGIOENDOTHELIOMA (Dabska’s tumor)
4. KAPOSI-LIKE INFANTILE HAEMANGIOENDOTHELIOMA
5. GIANT CELL ANGIOBLASTOMA
6. POLYMORPHOUS LOW-GRADE HAEMANGIOENDOTHELIOMA OF
LYMPH NODES
7. KAPOSI’S SARCOMA
III MALIGNANT VASCULAR TUMORS
1. ANGIOSARCOMA
- Idiopathic
- Associated with lymphedema
- Post-radiotherapy
- Epitheloid
2. “INTIMAL SARCOMA”
IV TUMORS OF LYMPH VESSELS
      1. LYMPHANGIOMA
- Lymphangioma circumscriptum
- Cystic hygroma
- Progressive lymphangioma (Lymphangioendothelioma)
2.   LYMPHANGIOMYOMA
       3.  LYMPHANGIOMATOSIS
- Lymphangiomatosis of the limbs
V TUMORS OF PERIVASCULAR CELLS
      1.  GLOMUS TUMOR
- infiltrating glomus tumor
       2. GLOMANGIOMA
 3. GLOMANGIOMYOMA
       4. GLOMANGIOSARCOMA
  5. HAEMANGIOPERICYTOMA
5.5.2.1. Hemangioma
Hemangioma is a benign vascular lesion and is the most common tumor in infancy
(Requena and Sangueza, 1997). Infantile hemangiomas are highly proliferative le-
sions involving aberrant localized growth of the capillary endothelium. They undergo
a rapid postnatal proliferative phase that lasts approximately one year followed by a
slow involution phase that lasts 5-10 years. The proliferative phase is marked by cel-
lular hyperplasia with and without lumens. It has been suggested that the presence of
large nuclei with scant cytoplasm within the endothelial cells of hemangiomas is a
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sign for cellular immaturity. In addition, early proliferative cellular hemangiomas
have been shown to lack certain differentiation markers spesific to endothelial cells.
For example, the cellular regions of hemangiomas lack Weibel-Palade bodies and do
not synthesize vWF (Yasunaga et al., 1989). Hemangiomas show increased expres-
sion of the human hematopoietic progenitor antigen CD34.
The involuted phase is marked by decreased cell turnover and cellularity, an
increased number of fully differentiated vessels and more interstitial fibrous and fatty
tissue. Based on clinical and histological observations, hemangiomas have been
hypothetized to represent angioblastic tissue that undergoes a delayed maturation.
Lesions often progress from predominantly unorganized cellular structures during the
proliferative phase to ones that have readily identifiable vascular channels at the time
of involution.
 Histological analyses of tissue specimens have provided important insights
into the cellular and molecular interactions within hemangiomas. While hemangiomas
are composed of a heterogeneous population of cells, it could be hypothesized that the
development of a hemangioma is the product of abnormal endothelial cell
proliferation, causing a mis-regulation of angiogenesis. An increase in the number of
mast cells has been demonstrated in the proliferative growth phase, and further, mast
cells have been shown to be a major source of the angiogenic cytokine, bFGF within
hemangiomas (Qu et al., 1995). Other promoters of angiogenesis present during the
proliverative phase are VEGF (Takahashi et al., 1995), type IV collagenase and E-
selectin (Kraling et al., 1996). In contrast, the involuted phase is marked by a
decrease in mast cells and angiogenic factors. Moreover the TIMPs have been shown
to be upregulated during the involuting phase. VEGF is produced by a heterogeneous
mixture of cells cultured from hemangiomas (Berard et al., 1997). Artificial gene
manipulation attemps towards angiogenesis therapy have provided additional
evidence for the importance of VEGF in the growth of hemangiomas. Murine
myoblasts expressing continuously VEGF165 induced intramural vascular tumors
resembling hemangiomas after injection to mouse myocardium (Lee et al., 2000).
This kind of hemangioma formation has also occurred when VEGF164-transduced
myoblasts were introduced to mouse leg muscles (Springer et al., 1998).
 Usually most hemangiomas occur sporadically and as a single lesions, or as
linked to pleiotropic genetic syndromes. The genetic defect for a novel familial form
of the infantile hemangioma can be localized to the short arm of chromosome 5
(Walter et al., 1999). It is of interest that the defective gene is localized to a region of
the chromosome 5 that codes for receptors involved in blood vessel growth, including
FGF receptor-4, PDGF-β and VEGFR-3.
5.5.2.2.  Lymphangioma
Lymphangiomas result from the abnormal development of the lymphatic sys-
tem, with prevention of lymph drainage from the affected area. Except for the eye and
neural tissue, lymphangiomas can originate in any organ although more than 95% oc-
cur in the soft tissues of the head and neck (cystic hygroma) and axilla, with less than
5% occurring in the abdominal cavity.
Macroscopically lymphangioma is a solitary, multicystic mass. The cysts may
connect with each other suggesting that they are dilated lymphatic channels. These
channels contain serous, serosanguinous, or chylous fluid. The lining of the cysts is
smooth and they have thin walls. Histological criteria for lymphangiomas have been
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defined by Enzinger: 1) lymphatic spaces lined by endothelium, 2) fascicles of
smooth muscle in the septa between the lymphatic spaces, and 3) lymphoid
aggregates in the delicate collagenous stroma (Enzinger and Weiss, 1995).
Lymphangiomatosis is a rare disorder which affects bones, parenchymal organs, and
Table 7. Summary of the expression of VEGF family members in vascular tumors.
GROWTH
FACTOR/
RECEPTOR
VASCULAR
LESION
RESULT REFERENCES
VEGF Pyogenic
granuloma
Strong in
proliferating cells
without vessel
lumen formation
(Bragado et al., 1999)
Hemangioma Weak/equivocal
 Proliferative
phase positive
(Brown et al., 1996)
(Takahashi et al., 1994)
Angiosarcoma
Aicardi sdr
Soft tissue
Cutaneous
Focal
Strong/moderate
High/Intermediate
Weak
(Hashimoto et al., 1995;
McLaughlin et al., 2000)
(Zietz et al., 1998)
(Brown et al., 1996)
Kaposi’s  sarcoma
AIDS associated
Mostly weak  Not
significant
(Brown et al., 1996)
(Skobe et al., 1999)
VEGF-C Kaposi sarcoma
AIDS associated Not significant (Skobe et al., 1999)
VEGFR-1 Hemangioma Strong (Brown et al., 1996)
Angiosarcoma
Aicardi sdr Strong, diffuse (McLaughlin et al., 2000)
Kaposi sarcoma
AIDS associated Strong (Skobe et al., 1999)
VEGFR-2
Hemangioma Strong (Brown et al., 1996)
Angiosarcoma
Aicardi sdr Strong, diffuse (McLaughlin et al., 2000)
Kaposi sarcoma
AIDS associated Strong (Skobe et al., 1999)
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GROWTH
FACTOR/
RECEPTOR
VASCULAR
LESION
RESULT REFERENCES
VEGFR-3 Hemangioma Almost negative (Fanburg-Smith et al.,
1999; Folpe et al., 2000)
Hobnail
hemangioma/Target
oid hemosiderotic
hemangioma
Positive (Mentzel et al., 1999)
(Fanburg-Smith et al.,
1999)
Papillary
intralymphatic
angioendothelioma
Positive (Fanburg-Smith et al.,
1999)
Angiosarcoma
Angiosarcoma
-no lymphedema
associated
Positive
50% cases
positive
(Breiteneder-Geleff et al.,
1999)
(Folpe et al., 2000)
(Fanburg-Smith et al.,
1999)
Kaposi sarcoma
- Classic
- AIDS associated
- not lymphedema
associated
Positive
Positive
Strong positivity
(Jussila et al., 1998)
(Folpe et al., 2000)
soft tissues by diffuse proliferation of lymphatic channels (Gomez et al., 1995).
Immunoelectron microscopic studies have demonstrated upregulation of CD31 and
CD34 and show type IV collagen expression in lymphangiomas (Sauter et al., 1998).
Furthermore, as yet molecularly undefined PAL-E was confined to blood vessels in
lymphangiomas. Light microscopy is not always able to detect CD34
immunoreactivity (Paal et al., 1998). Data on the VEGF- and Tie family members in
the tumors of lymph vessels is scant. But VEGFR-3 mRNA has been localized to a
human lymphangioma (Kaipainen et al., 1995).
A mouse model for lymphangioma was established by Mancardi et al (Mancardi et
al., 1999). By injecting incomplete Freund’s adjuvant intraperitoneally to nude mice
the authors were able induce tumors that fulfill Enzinger’s criteria for a
lymphangioma. In addition to VEGFR-1 and VEGFR-3, the newly formed tumor
endothelium was found to express intracellular adhesion molecule-1/CD54.
5.5.2.3. Angiosarcoma
Recent publications link human herpes virus 8 and two other lympho-proliferative
disorders: multicentric Castleman's disease (Cesarman et al., 1995; Soulier et al.,
1995) and a newly recognized disease, body-cavity-based lymphoma or primary effu-
sion lymphoma (Knowles et al., 1989). Also an association between angiosarcoma
and HHV-8 has been shown (Remick et al., 2000). All of these tumors are character-
ized by the abnormal proliferation of the vascular endothelium, a putative cellular tar-
get of human herpes virus-8 infection.
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 Cutaneous angiosarcomas can be caterigorized into three types: 1) Wilson
Jones angiosarcoma affecting the face and scalp of elderly patients, 2) lymphedema
associated AS and 3) radiation-induced AS. Angiosarcoma represents 2% of all soft
tissue sarcomas and most typically it appears 10 years after mastectomy in
lymphedematous arms (Stewart-Treves syndrome). Lymphedema is thought to
modify the biochemical or immunological status of the affected limb, fostering the
development of angiosarcoma. It has been noted that skin grafts survive for long
periods when transferred to lymphedematous extremities, suggesting that chronically
affected lymphedematous sites are “immunologically privileged” (Stark et al., 1960).
Tables 7 and 8 show that angiosarcomas have been studied extensively. The data
indicate that many of the VEGF and Tie family members are involved.
5.5.2.4. Kaposi’s sarcoma
Kaposi’s sarcoma (KS) is a multicentric neoplasm of vascular origin and very
probably HHV-8 or KS-associated herpes virus etiology (Chang et al., 1994). The ka-
posin oncogene of the HHV-8 is able to induce tumorigenic transformation, has been
found to be expressed in the spindle shaped cells of this tumor (Ganem, 1997; Mu-
ralidhar et al., 1998; Staskus et al., 1997). These categories of KS including the “clas-
sical” in older males of mainly Mediterranean or Eastern European Jewish back-
grounds; “endemic”, found in parts of equatorial Africa; “iatrogenic”, immunosup-
pressive drug-associated KS and AIDS associated KS all express the oncogene. Not
all HIV-positive patients get KS, and that may be because they lack kaposin as a
sexually transmitted agent or co-factor.
Histologically, in early KS lesions, which normally appear on the skin, there is
a collection of small, irregular, endothelial-lined spaces that surround normal dermal
blood vessels (Gallo, 1998). These are accompanied by a variable, inflammatory
infiltrate of lymphocytes, known as the patch stage. This is followed by the expansion
of the spindle-cell vascular process throughout the dermis. These spindle cells form
slit-like vascular channels containing erythrocytes (the plaque stage). The later,
nodular-stage KS lesions are composed of sheets of spindle cells, some of which are
undergoing mitosis, and slit-like vascular spaces which have areas of haemosiderin
pigmentation. The spindle cells form the bulk of established KS lesions, but based on
chromosomal analysis they are not neoplastic (Gallo, 1998).
  The majority of the spindle cells stain for endothelial cell markers, though
evidence for smooth muscle cell, macrophage, dendritic cell and multipotential cell
origin also exists (Kaaya et al., 1995). High local levels of cytokines such as
interleukin 6 (IL-6), basic fibroblast growth factor (bFGF), tumour necrosis factor- α
(TNF-α), interferon-γ and VEGF have been isolated from KS lesions (Ensoli et al.,
1989; Miles et al., 1990) (Nakamura et al., 1988). Interestingly, the HIV Tat protein,
that transactivates transcription of HIV, specifically binds and activates VEGFR-2
(Albini et al., 1995). It has been shown that the Tat basic domain contains an
arginine- and lysine-rich sequence that is similar to that of the potent angiogenic
growth factors, VEGF and FGF (Albini et al., 1996). KSHV encodes a G protein-
coupled receptor (GPCR) that switches on the angiogenesis by inducing the
production of VEGF (Munshi et al., 1999). VEGF-C has been found to be  strongly
expressed by the blood vessels surrounding blood vessels the KS, but not the spindle
shaped cells (Skobe et al., 1999). As table 7 shows VEGFR-1, VEGFR-2 and
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VEGFR-3 are strongly expressed in the spindle cells of KS. However, no study was
available in which these factors had been analysed from the same sample.
Table 8. Summary of the expression of Tie family members in vascular tumors.
GROWTH
FACTOR/
RECEPTOR
VASCULAR
LESION
EXPRESSION REFERENCES
Tie-1 Angiosarcoma
Cutaneous Strong (Brown et al., 2000)
Kaposi’s sarcoma
AIDS associated Mostly strong  (Brown et al., 2000)
Tie-2 Angiosarcoma
Cutaneous Strong (Brown et al., 2000)
Kaposi’s sarcoma
AIDS associated Mostly strong  (Brown et al., 2000)
Angiopoietin-1 Angiosarcoma
Aicardi sdr
Soft tissue
Kaposi’s  sarcoma
HIV-positive
Not clear
Low
Strong
(McLaughlin et al.,
2000)
(Brown et al., 2000)
Angiopoietin-2 Angiosarcoma
Aicardi sdr
Soft tissue
Kaposi’s sarcoma
HIV-positive
Very
strong,diffuse
Low
Strong
(McLaughlin et al.,
2000)
(Brown et al., 2000)
Angiopoietin-4 Angiosarcoma
Aicardi sdr
Cutaneous
Kaposi sarcoma
HIV-positive
Not clear
Equivocal
Low/equivocal
(McLaughlin et al.,
2000)
(Brown et al., 2000)
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AIMS OF THE PRESENT STUDY
We wanted to elucidate the specificity of the recently cloned growth factors and
receptors of the lymphatic vasculature and to explore their usefulness in molecular
identification of lymphatic vascular structures, for which no molecular antigenic
markers have been previously presented. Also, no proper attempt to distinguish dif-
ferent types of vascular tumors and vascular malformations has been made by as-
sessing molecular markers for angiogenic growth factors and receptors. Instead, the
widely used classification of the International Society for the Study of Vascular
Anomalies is still based on the clinical and histological observations.  The general
aim of this study was thus to investigate angiogenic molecules as endothelial cell
markers.
The specific aims of the study were:
1. In vivo analysis of VEGF-C and VEGF in human skin and verifying VEGFR-2
and VEGFR-3 in the dermal vasculature.
2. Assessment and comparison of VEGFR-3 and podoplanin as lymphatic markers in
Kaposi’s sarcoma, and in Kaposi’s sarcoma-derived cell cultures.
3 .  Locate the known endothelial growth factor receptors in human fetal heart
vasculature.
4. Analyze the expression of VEGFR-3 in vascular tumors and analyze the condi-
tions where anti-VEGFR-3 antibodies can be used as markers for endothelia of
lymphatic origin.
5. Establish the normal expression patterns of VEGFR-3 and its ligands, VEGF-C
and VEGF-D in various human tissues.
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MATERIALS AND METHODS
1. Materials
1.1. Tissue specimens
All fetal tissues included in this study have been obtained from legal abortions of
healthy women induced with prostaglandins. The gestational age was estimated from
the foot length (Munsick, 1984). Tissue samples had been fixed in 4% paraformalde-
hyde for 20 hours, dehydrated, and paraffin-embedded for sectioning.
All the other specimens, histologically normal adult tissues and tumor samples
were fixed in 4% phosphate–buffered formaldehyde immediately after removal, and
transported to the Department of Pathology, University of Helsinki, or in the case of
KS samples (for details, see original publication II) to the Institute of Clinical
Pathology and the Department of Dermatology, University of Vienna or in case of
vascular tumors (for details, see original publication IV) to the Department of Soft
Tissue Pathology, the Armed Forces Institute of Pathology, Washington, DC. The
vascular tumors were classified according to Enzinger and Weiss (Enzinger and
Weiss, 1995).
1.2. Antibodies for immunocytochemistry and Western analysis
The antibodies used in this study are listed in tables 9 and 10. In the previously un-
published studies the following antibody concentrations/dilutions were used:  VEGF-
C (hybridoma culture fluid of clones #9H7F10, 2C1D11, 9H7C12 and 9H7H3) 1:2;
VEGF-C (882) 1.5µg/ml; VEGF-D (#78939.11, 78923.11 and  78935.11) 10µg/ml;
VEGF-D (VD1) 2.9µg/ml; VEGF-D (#N19) 1:250-300, VEGF-D (749-1AP)
0,2µg/ml; VEGFR-1 1:200 dilution of the supernatant of clone 19 and VEGFR-2
1:800.
Table 9. Summary of the antibodies used specifically in detecting VEGFs and Tie-
receptors.
ANTIBODY SOURCE REFERENCE PEPTIDE USED IN
VEGF
Monoclonal
Clone#
26503.11
 Santa Cruz
Biotechnoloy, CA
V
Polyclonal
N19
SantaCruz
Biotechnoloy, CA
V
VEGF-C
Monoclonal
clone#
2C1D11 Dr K. Alitalo Baculo V
9H712 Dr K. Alitalo Baculo V
9H7H3 Dr K. Alitalo Baculo V
9H7F10 Dr K. Alitalo Baculo V
Polyclonal
882
Dr K. Alitalo (Joukov et al.,
1997)
Aa residues
104-120 of the
VEGF-C
prepropeptide
V
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C20 Santa Cruz Corresponding to
aas 400-419
V
VEGF-D
Monoclonal
clone#
78923.11 R&D V
78935.11 R&D V
78939.11 R&D V
VD1 Dr M. Achen (Achen et al.,
2000) V
VEGF-D
Polyclonal
N19 Santa Cruz Corresponding
to aas 22-40 V
749-1AP R&D (Barleon et al.,
1997)
V
VEGFR-1 R&D (Simon et al.,
1998)
Human soluble
Flt1 protein
(domain 1-5)
V
VEGFR-2 Dr H. Weich (Simon et al.,
1998)
Baculovirus III
Neuropilin-1 Dr H.
Kitsukawa
(Kitsukawa et
al., 1995)
aas 483-856 of
mouse neuropilin
III
VEGFR-3
Monoclonal
clone #
9D9F9 Dr. K. Alitalo
(Jussila et al.,
1998)
EC domain of
VEGFR-3 in a
Baculovirus
I, II,  III,
IV, V
Tie-1
Monoclonal
clone #
7E8 Dr. K. Alitalo (Salven et al.,
1996)
EC domain of Tie III
10F11 Dr. K. Alitalo         -“- -“- III
Tie-2/Tek
Monoclonal
clone # Dr T. Suda
(Yano et al.,
1997) III
Podoplanin Dr D.
Kerjaschki
(Breiteneder-
Geleff et al.,
1997) II
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Table 10. Summary of the commercial antibodies used in this study.
COMMERCIAL
ANTIBODIES
SOURCE STUDY
CD31 (platelet/endothelial
cell adhesion molecule 1)
DAKO Immunoglobulins, Glostrup,
Denmark
I, II, III & V
CD34 (clone QBEND) DAKO Immunoglobulins, Glostrup,
Denmark
IV
CD34 (clone QBEND) Immunotech, Westbrook, Maine II
CD31 (clone JC/70) DAKO, Carpinteria, CA IV
CD68 Becton Dickinson, San Jose,
California
II
vWF (von Willebrand
factor/factor VIII-related
antigen)
DAKO Immunoglobulins, Glostrup,
Denmark
I, III
PAL-E (an as yet molecularly
undetermined vascular
marker)
Serotec, Oxford, United Kingdom II
PAL-E Sanbio, Uden, The Netherlands III
laminin Sigma Chemical Co, St.Louis, MO I
Desmoplakin 1&2 Progen Biotechnik GmbH III
α-smooth muscle actin, clone
19
Sigma Chemical Co, St.Louis, MO III
α-smooth muscle actin, clone
1A4
Sigma Chemical Co, St.Louis, MO V
Insulin DAKO, Carpinteria, CA V
Glucagon DAKO, Carpinteria, CA V
Somatostatin DAKO, Carpinteria, CA V
Chromogranin A DAKO, Carpinteria, CA V
Gastrin DAKO, Carpinteria, CA V
Serotonin DAKO, Carpinteria, CA V
Glial fibrillary acidic proteon DAKO, Carpinteria, CA V
Adrenocorticotropin DAKO, Carpinteria, CA V
Growth hormone DAKO, Carpinteria, CA V
S-100 DAKO, Carpinteria, CA V
Neurofilament 200 Boehringer Mannheim,
Germany
V
1.3. Probes for in situ hybridization and Northern analysis
Each tyrosine kinase receptor or ligand cDNA sequence was subcloned into an
appropriate transcription vector with RNA polymerase promoters on either side of the
insert. The plasmids were linearized by restriction endonuclease digestion and puri-
fied. Sense and antisense radiolabelled RNA probes were obtained via the incorpora-
tion of (35S)UTP on addition of specific polymerases. Synthesis of radioactive RNA
was followed by treatment with DNAase I and partial alkaline hydrolysis of RNA to
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obtain fragments of appropriate length. The probes thus produced are listed in table
11.
Table 11. Summary of the probes used in this work.
cDNA Plasmid cDNA source Nucleotides Used in
hVEGFR-2 pBS K II SK+ Dr Arja Kaipainen 6-715 I, V
hVEGFR-3 pGEM 3Z (f+) Dr Arja Kaipainen 1-595 I, V
hVEGF-C pREP7 Dr Vladimir Joukov 494-1661 V
hVEGF-D pcDNA3.1 Taija Mäkinen 411-1685 V
1.4. Primary cell culture
Cultures of spindle cells (table 12) derived from KS tissue were established by
explant culture method (M7/2, M12/4) or by enzymatic dissection (M7Col12,
M12T8) of  KS biopsies from skin of two male patients with AIDS (M7, M12). Cells
were maintained in Dulbecco’s minimal essential medium with 10% fetal bovine se-
rum as previously described (Roth et al., 1988) (Roth et al., 1989). KS spindle cells
were characterized by cytochemical staining and were positive for Ulex europaeus
antigen-1 and BMA120.
KS Y-1 is a autonomously growing KS-derived tumor cell line and a kind donation
from Dr. M.Reitz. Human umbilical vein endothelial cells were cultured as described
earlier (Weninger et al., 1998).
Table 12. The primary cell cultures used in this work.
CELL LINE DESCRIPTION SOURCE USED IN
M7/2 human KS * (Pammer et al., 1996) II
M12/4 human KS* (Pammer et al., 1996) II
M7Col 12 human KS† (Pammer et al., 1996) II
M12T8 human KS† (Pammer et al., 1996) II
KS Y-1 human KS (Lunardi-Iskandar et al., 1995) II
HUVEC Umbilical vein EC (Weninger et al., 1999) II
Abbreviations: KS, Kaposi’s sarcoma; * explant culture; †enzymatic dissection.
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Table 13.
Northern blot Description Source Used in
Human endocrine system Multiple tissue mRNA Clontech V
1.5. Receptor-binding analysis using iodinated growth factors
The growth factors listed in table 13 were labeled with 125I using the Iodo-Gen
reagent (Pierce, Rockford, IL) and purified by gel filtration on PD-10 columns
(Pharmacia, Uppsala, Sweden). The specific activities were 2.2x105cpm/ng and
1.0x105cpm/ng for rh-VEGF and rh-VEGF-C, respectively. The iodinated growth
factors were tested for specific binding using PAE-VEGFR-1 and VEGFR-3 cells
(Joukov et al., 1997) and soluble receptor proteins (Achen et al., 1998). For details,
see the original publication (I).
Table 14.
GROWTH FACTORS SOURCE OR REFERENCE USED IN
Rh VEGF165 R & D Systems I
VEGF-C 21-kd (Joukov et al., 1997) I
2. METHODS
2.1. Immunocytochemistry
In all studies indirect immunocytochemistry was used, using a secondary antibody
against the primary antibody, and the antibody complexes were detected by the
avidin-biotin-peroxidase complex (ABC)-technique (Hsu and Raine, 1981).
In both formalin and paraformaldehyde-fixed paraffin-embedded tissues, VEGFR-
3 antigenicity had to be recovered before staining by high-temperature heating of
sections. The citrate-mediated high-temperature antigen retrieval alone gave only a
very weak staining result but when it was combinated with commercial tyramide
signal amplification system (TSATM by NEN® Life Science Products, Inc., Boston,
Mass.) staining result of the 4% paraformaldehyde fixed material was successful. The
best staining result was achieved by heating the slides for 20 min in 0.05M Tris-Hcl
buffer containing 0.1% Tween (DAKO®antibody diluent with background reducing
components) at 98°C and using DAKO’s antibody diluent. The latter protocol has
turned out to be the most useful one especially in formalin-fixed material. For details,
see the original publications (I-V). Negative controls were done by omitting the
primary antibody, using irrelevant primary antibody of the same isotype, or blocking
the anti-VEGFR-3 and the anti-VEGF-C by overnight incubation with a 10-fold molar
excess of the immunogen (Joukov et al., 1997; Jussila et al., 1998). VEGF-D
blocking was done with a 40-fold molar excess of the immunogen for 1 h at room
temperature.
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Table 15. Summary of the methods used in this work.
METHODS USED IN
Immunohistochemical staining I, II, III, IV, V
Preparation of human fetal and adult tissues I, III, V
RNA isolation II
RNA in situ hybridization I
RT-PCR II
Northern blotting II, V
Immunofluorescence staining II, V
Protein radioiodination I
Confocal  laser microscopy II
Cell culture II
Flow cytometry II
2.2. In situ hybridization (I)
For in situ hybridization, 4µm cryostat sections were cut onto sterile glass slides
pretreated with 2% 3-aminopropyltriethoxysilane in acetone, and fixed in 4% para-
formaldehyde. The hybridization was performed as described by Wilkinson et al
(Wilkinson et al., 1987) with some modifications. After the hybridization the sections
were washed at low stringency conditions (2x saline-sodium citrate buffer (SSC), 20
mmol/L dithiotreitol) for 30 min at 65°C. The slides were then coated with the NTB2
Kodak emulsion, incubated for 2-8 weeks and developed with Kodak D19 developer
for 4 min. Post-fixation was done with Kodak Unifix for 4 min, and thereafter the
slides were counterstained with Mayer’s hematoxylin, dehydrated and finally
mounted in Permount. The controls included hybridization with sense probes, as well
as unhybridized slides..
2.3. Iodinated growth factor binding (I)
 Frozen sections were cut at 7µm from adult human skin. The sections were
mounted onto silane-coated slides and stored in air-tight boxes at –70°C. After thaw-
ing, the sections were incubated for 30 min at room temperature in the blocking solu-
tion, [MEM (Gibco), 0.5mg/ml BSA, 20mM Hepes pH 7.4, 1mM PMSF and 4 µg/ml
leupeptin]. The blocking buffer was then removed and the sections were covered by a
droplet of the same buffer containing 10 pM 125I-rh VEGF or 10pM 125I-rh-VEGF-C.
To define non-specific binding, adjacent sections were incubated in the same concen-
tration of iodinated growth factor in the presence of 1nM of the corresponding non-
labeled growth factor. After 90-minute incubation in a humidified chamber at room
temperature, the sections were rinsed for 5x3 minutes on ice, once with the binding
buffer and four times with phosphate-buffered saline (PBS). Sections were the fixed
for 10 min in 2% paraformaldehyde, 2% glutaraldehyde in 0.1M phosphate buffer pH
7.4, rinsed for 2-5 s in dH2O, and dried at room temperature for approximately 2 h.
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The dried sections were covered with NTB-2 emulsion (Eastman Kodak Co., Roch-
ester, NY) and stored at 4°C for 2 weeks, developed and stained.
2.4. Fluorescence microscopy (II, V)
Expression of VEGFR-3 and podoplanin  was studied by fluorescence micros-
copy on acetone fixed cryosections of two HIV-1-positive and two HIV-1-negative
KS samples. For double staining the sections were sequentially incubated with anti-
VEGFR-3 or anti-podoplanin antibodies at 4°C overnight, followed by tetrarho-
damine isothiocyanate (TRITC)- and FITC-labeled second step reagents, respectively.
After incubation with 10% normal mouse serum, the anti-VEGFR-3 sections were
reacted with FITC-labeled anti-CD31 mAb (1,5 mg/ml, Alexis Corp., San Diego,
California) or FITC-labeled anti-CD68 mAb (1:2000), Beckton Dickinson, San Jose,
California; kindly provided by Dr. O.Majdic, Vienna). The podoplanin labeled sec-
tions were incubated with anti-CD31 (1:250), Becton Dickinson), anti-PAL-E (1:200)
or anti-VEGFR-3 (1µg/ml) followed by TRICHH-labeled goat anti-mouse serum
(1:100, Jackson Immuno Research Laboratories, Westgrove, Pennsylvania). Sections
were evaluated by using a confocal laser microscope (LSM 410, Zeiss, Oberkochen,
Germany). Appropriate isotope matched controls were run in parallel, and these con-
sistently showed no reactivity.
2.5. Northern analysis (V)
The probes listed in table 11 were labelled by the random priming method and in-
cubated with the blot (table 12) in ULTRAhyb solution at 55°C overnight, followed
by washes in high stringency conditions and exposure in PhosphoImager.
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RESULTS AND DISCUSSION
1. Expression of the Vascular endothelial Growth factor C Receptor VEGFR-3
in Lymphatic Endothelium of the Skin and in Vascular Tumors (Study I)
The microvasculature of the skin was characterized by early morphological stud-
ies in the 1950s and 1960s. Remarkably, the cutaneous lymphatic network has been
rather neglected, probably due to the lack of specific markers. A limited number of
ultrastructural studies showed that the structure of the cutaneous lymphatics to be
markedly different from that of vascular capillaries (Berens von Rautenfeld et al.,
1987; Leak and Burke, 1966). Lymphatics are flattened tubes lined by an extremely
attenuated endothelium encompassed only by sub-endothelial “basal lamina-like”
material, whereas surrounding pericytes are lacking (Ryan, 1989). The lymphatic en-
dothelium contains very few pinocytotic vesicles and lacks Weibel-Palade bodies and
fenestration.
Based on previous observations of VEGFR-3 expression by in situ analysis, we
assumed that the monoclonal antibody against the receptor EC domain detected only
the lymphatic endothelium, after organogenesis (Jussila et al., 1998; Kukk et al.,
1996). In the normal human skin this turned out to be true. Furthermore, the
endothelium of the skin or soft tissue affected by lymphangiomatosis was strongly
stained for VEGFR-3, compared to that of normal dermal lymphatics, indicating up-
regulation of the receptor in that rare disorder.
 In vivo analysis VEGF-C by protein radio-iodination, showed the growth
factor binding to the lymphatic vessels of the upper dermis whereas VEGF bound
throughout the extending dermal vascular endothelium. Indeed, over-expression of
VEGF-C under the keratin 14 promoter has been shown to cause hyperplasia of
lymphatic vessels (Jeltsch et al., 1997), a condition that mimics lymphangiomatosis in
humans (personal communication with C.M.D. Fletcher). It would thus be of interest
to determine if patients with lymphangiomatosis suffer from genetic alteration in the
coding region of VEGF-C. This would not be surprising considering the early
occurrence of this disease mainly in children or during the first two decades of life
and the fact that lymphatics differentiate probably as the last endothelium lined
structure of vascular tree (Gomez et al., 1995).
The findings documented here indicate that VEGFR-3 is distributed in a manner
consistent with the known lymphatic vascular pattern in human skin as shown by
specific radioactive ligand binding, receptor in situ hybridization, and
immunohistochemistry.
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2. Expression of Vascular Endothelial Growth Factor Receptor-3 and
Podoplanin Suggests a Lymphatic Endothelial Cell Origin of Kaposi’s
Sarcoma Tumor Cells (Study II)
 One of the most asked questions about the pathogenesis of KS is: Which cell
type gives rise to the spindle shaped cells that characterize the late stage of the dis-
ease? KS is commonly thought to be derived from endothelial cells because of the
predominant expression of endothelial markers, CD34, VE-cadherin, vWF and endo-
thelial leukocyte adhesion molecule type 1 in KS lesions (Samaniego et al., 1998).
However, the heterogeneity of the spindle-cell compartment makes the precise lineage
relationship of KS tumor cells unclear.
Some cultured KS-derived spindle cells constitutively overexpress antiapop-
totic proteins and exhibit invasive properties, which suggest that they may adequately
represent the tumor cells of KS (Mori et al., 1999). Interestingly, KS-derived spindle
four cell cultures did not express VEGFR-3 or podoplanin in our studies. This may
reflect generally the problem that in the course of cell culture, the original antigenic
phenotypes are easily lost or as the second explanation the cultured cells are not re-
lated to the tumor cells in KS lesions. Absence of other KS markers, CD31 and CD34
supports the former alternative. HHV-8 is lacking from the KS- cell cultures which
gives further support to that (Lunardi-Iskandar et al., 1995). However, there are also
VEGFR-2 and VEGFR-3 expressing KS-cell cultures, too, that can be stimulated by
VEGF-C (Liu et al., 1997; Skobe et al., 1999). The mitogenic effect of VEGF-C on
KS-cells is mediated through VEGFR-2 because a recombinant point mutant of
VEGF-C that binds and activates selectively VEGFR-3 did not induce endothelial cell
migration (Joukov et al., 1997). Until now, no data is available about the role of
VEGF-D, the other ligand for VEGFR-2 and VEGFR-3, in the pathogenesis of KS.
Recently, it was suggested that spindle cells are derived from myofibroblasts
(Simonart et al., 2000). The authors concluded that in histological sections the promi-
nent growth of endothelial cells is a reactive hyperplasia and showed by myofibro-
blast antigens in their cultured KS-cells. Our immunohistochemical results are in ac-
cordance with this view. The consistent expression of VEGFR-3 on both the very
early stage of KS, which is characterized by endothelial cell activation and prolifera-
tion and inflammatory cell infiltration, and KS tumor cells in nodular lesion deepened
earlier data from our laboratory where we showed the antigen in spindle cells (Jussila
et al., 1998). In the light of present knowledge about VEGFR-3’s role in the mainte-
nance of endothelial lining integrity in tumor vasculature, the antigen is needed for
survival signaling in KS cells as well (Kubo et al., 2000). By immunohistochemical
staining of serial sections and immunofluorescence double labeling, VEGFR-3 im-
munopositive cells of early and late lesions shared an identical phenotype and were
negative for CD68, CD45, and PAL-E, but were positive for CD31 and CD34. This
antigenic profile excluded that VEGFR-3 positive cells represent sinus lining cells of
lymph node, macrophages, and cells of hemopoietic lineage in general. Northern hy-
bridization and RT-PCR assessment confirmed VEGFR-3 mRNA in KS lesions. Fur-
ther, KS had been shown to be immunopositive for VEGFR-3, irrespective of origin
(Jussila et al., 1998).
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 Our study was based on the assumption that anti-VEGFR-3 antibody detects only the
lymphatic endothelium. Previous studies on the antigen have changed that view
(Valtola et al., 1999). Additional evidence for the relationship of KS tumor cells to
lymphatic EC came from human podoplanin expression studies (Breiteneder-Geleff et
al., 1999). This membrane glycoprotein, which was originally identified on podocytes
in rat glomerular cells, is expressed on lymphatic but not blood vessel EC. It is pre-
sent on lymphangiomas, early intestinal KS, variable present on angiosarcomas, but
absent from tumor cells in hemangiomas. All KS tumor cells and cells lining vascular
slits in early as well as in late KS lesions homogeneously express podoplanin. Stain-
ing patterns for podoplanin and VEGFR-3 were overlapping, as detected by confocal
laser microscopy.
Even though several authors have suggest a lymphatic derivation of KS
spindle cells from lymphatic endothelia, the confirmation of this hypothesis has been
impossible because of the lack of specific lymphatic markers. Based on present
knowlegde about VEGFR-3 we can not be sure if KS-cells are of lymphatic
endothelial origin. On the other hand, the information about podoplanin contribution
to vasculogenesis and angiogenesis is lacking completely and not very much is known
about its biological function in normal vasculature. One possibility is that the KS
clonogenic cells have circulating mesenchymal stem cell properties.
3.  Endothelial Growth Factor Receptors in Human Fetal Heart (Study III)
Transfecting genes encoding angiogenic cytokines, particularly those naturally se-
creted by cells, may constitute an alternative treatment strategy for patients with ex-
tensive tissue ischemia, in who contemporary therapies (anti-anginal medication, an-
gioplasty, bypass surgery) have previously failed or are not feasible (Ferrara and Ali-
talo, 1999). Therapeutic angiogenesis is designed to promote the development of sup-
plemental collateral blood vessels, which will constitute endogenous bypass conduits
around occluded native arteries. When using such techniques, it is essential to map the
ligand binding receptors, and thus estimate the consequences, or side effects of the
given growth factor. The former was done for human fetal heart tissue.
The immunohistochemical approach supported previous findings of VEGFR1,
VEGFR-2 and VEGFR-3 receptor tyrosine kinases in the human fetal heart, except
that in the present study, a minor population of the myocardial capillaries also
contained VEGFR-3 in 13- to 30-week fetuses (Kaipainen et al., 1993). However,
while the analysis with in situ hybridization suffers from morphological insensitivity,
with immunohistochemistry the structures could be better recognized. This allowed us
to report the specificity of these important receptors in different types of heart vessels
in great structural detail. Furthermore, besides VEGFR-3, we were able to
demonstrate that VEGFR-2 and both of the Tie-receptors are present in lymphatic
vessels. The more intense staining of VEGFR-3 in 5-week embryos suggest that the
expression is downregulated in the blood vessels during the first trimester. VEGFR-1
and NP-1 showed overlapping expression patterns. A notably strong co-expression of
VEGFR-1, VEGFR-2, NP-1, Tie-1, and Tie-2 was associated with the endocardial
endothelium, which is subject to considerable degree of hemodynamic stress.
Conversely, VEGFR-3 was not detected in the endocardium or other subject to shear
stress.
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The assembly and maintenance of a functional vasculature likely requires the
orchestration of a variety of endothelial growth factors and receptors, which play roles
at different stages of the process. Even though VEGFR-1 and VEGFR-2 were
expressed in the same structures, only the former located to coronary arteries and
myocardial capillaries. Unlike all the other receptors VEGFR-3 was not detected in
the blood vessels or in the endocardium. Although VEGFR-3 is abundant in the early
stages of cardiovascular development, it later seems to take part in more specialized
biological functions preferably those of lymphatic endothelia. When compared with
fetal frozen sections, the adult heart samples showed qualitatively same results.
Further studies will need to be established to find out if these endothelial growth
factor receptor expression patterns are altered in an ischemic adult heart.
4. Lack of Lymphatic Vascular Specificity of Vascular Endothelial Growth
Factor Receptor 3 in 185 Vascular Tumors (Study IV)
The origin of various vascular lesions, lymphatic or blood endothelium has
prompted much debate. The staining with anti-VEGFR-3 antibodies also suggested
the lymphatic origin of KS spindle shaped cells (Jussila et al., 1998). In the subse-
quent study both classical and AIDS-associated KS forms were therefore studied
along with a panel of 185 vascular endothelial tumors, both benign and malignant.
This revealed that the VEGFR-3 antibody is not suitable for distinguishing the blood
vascular or lymphatic origin of tumor endothelium. The receptor was widely ex-
pressed among benign and malignant vascular tumors in adults as well as children.
Moreover, the VEGFR-3 is switched on the newly developed blood capillaries around
the tumor which makes it even a bigger problem in the identification of lymphatic
vessels. Thus anti-VEGFR-3 antibody detects both the lymphatic vessels and blood
capillaries induced by the tumor. Considering its expression, it is of interest that re-
cently, the biological function of VEGFR-3 in the tumor neovasculature was associ-
ated with the maintenance of the endothelial cell lining during tumor angiogenesis
(Kubo et al., 2000).
Most capillary hemangiomas, tumors with blood-filled vessels, were positive
for VEGFR-3, highlighting the extensive distribution of VEGFR-3 in proliferating
vessels of non-lymphatic nature. Although VEGFR-3 expression was present in most
infantile capillary hemangiomas, it was equally seen in capillary hemangiomas of
adults, including pyogenic granulomas, reactive vascular proliferations related to
lobular capillary hemangiomas. In contrast, in a recent study only 2/13 hemangiomas
stained for VEGFR-3 that gives a view of more spesific marker for lymphatic
endothelial cells (Folpe et al., 2000). The difference between our study and the one by
Folpe et al can be explained by the antigen retrieval process.
Among strongly positive vascular tumors were spindle cell hemangiomas
(hemangioendotheliomas) and Kaposiform hemangioendotheliomas, specific types of
proliferative vascular lesions the former now being interpreted as benign and the latter
belonging to the category of hemangioendotheliomas implying borderline malignant
status (Mills et al., 1980; Perkins and Weiss, 1996). Although the strong expression of
VEGFR-3 would be consistent with lymphatic differentiation, the extensive
erythrocyte content in the vascular lumina of these lesions supports the idea that
VEGFR-3 expression in these tumors reflects a proliferative vascular phenotype
rather than their lymphatic phenotype.
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The reactivity of VEGFR-3 with the majority of angiosarcomas, including the
poorly differentiated ones with limited or no vasoformation, indicates that this
receptor is generally conserved upon malignant transformation. It appears to be an
equally sensitive marker for endothelial differentiation of malignant vascular tumors
as CD31, especially in the group of non-epithelioid vascular tumors which were
positive in 87% of cases. However, VEGFR-3 is more specific for endothelia than
CD31, which also reacts with platelets and subsets of leukocytes. VEGFR-3 also has
advantage over CD34 and BNH9 in specificity, as the latter markers are positive in a
variety of fibroblastic tumors and carcinomas, respectively. The absence of VEGFR-3
in non-endothelial cell tumors such as malignant melanoma, undifferentiated
carcinomas and sarcomas further indicates that VEGFR-3 is a useful supplementary
lineage marker to identify endothelial differentiation in human sarcomas and should
be included in the immunohistochemical panel to evaluate the possible endothelial
cell differentiation of poorly differentiated neoplasms.
Post-mastectomy angiosarcomas, often also referred to as
lymphangiosarcomas were consistently VEGFR-3 positive, similar to the majority of
other angiosarcomas (Aygit et al., 1999). Considering the wide distribution of
VEGFR-3 in benign and malignant vascular tumors, its expression in post-
mastectomy angiosarcoma cannot be specifically interpreted to indicate lymphatic
origin. Usually angiosarcomas express mixed endothelial phenotypes of blood and
lymphatic capillaries (Breiteneder-Geleff et al., 1999). Based an assumption of
podoplanin as a specific marker for lymphatic endothelium angiosarcomas could be
divided into three categories (low, moderate and high) according to their podoplanin
expression. In a study by Folpe et al, 50% (8/16) of angiosarcomas were strongly
positive VEGFR-3; of the positive cases, six had either a prominent lymphocytic
infiltrate or hobnail endothelial cells (Folpe et al., 2000).
Epithelioid vascular tumors form a spectrum of benign, borderline (low grade
malignant) and high grade malignant tumors as represented by epithelioid
hemangioma, epithelioid hemangioendothelioma and epithelioid angiosarcoma.
Common to all these lesions is the epithelioid appearance of the lesional endothelial
cells by their ample cytoplasm previously described as “histiocytoid”. While the
benign epithelioid hemangiomas and borderline/low grade epithelioid
hemangioendotheliomas were positive in a third of the cases, the epithelioid
angiosarcomas were positive in 50% of the cases.  If these lesions are assumed to
represent a spectrum of transformation of the same phenotype, the increasing
frequency of VEGFR-3 expression from benign to malignant epithelioid vascular
tumors may suggest that VEGFR-3 is upregulated during malignant transformation.
Another finding that suggests upregulation of VEGFR-3 upon transformation is the
strong immunoreactivity commonly seen in angiosarcomas.
A consistent finding in this study was the common VEGFR-3-reactivity in the
cytologically benign capillary tumor neovascularization seen in both vascular and
non-vascular tumors, including carcinomas, sarcomas and lymphomas. This finding
suggests that VEGFR-3 is important for the genesis of tumor-induced
neovascularization, and raises the question of its role in angiogenesis of physiological
(wound healing) and pathological but nonmalignant diseases, such as diabetic
retinopathy, atherosclerosis, psoriasis, and rheumatoid arthritis. In cutaneous wound
healing, angiogenic blood vessels lack the antigen (Paavonen et al., 2000).
Immunohistological data about inflammatory conditions is absent but
proinflammatory cytokines, TNF-α and IL-1β  induced increase in VEGF-C in human
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lung fibroblasts whereas VEGFR-3 mRNA did not alter by IL-1β  (Ristimaki et al.,
1998).
Studies on other VEGFRs have shown strong VEGFR-2 mRNA expression in
Kaposi’s sarcoma and angiosarcoma, whereas capillary hemangiomas express both
VEGFR-1 and VEGFR-2 (Brown et al., 1996; Hashimoto et al., 1995). In the
pathogenesis of angiosarcoma VEGF, a ligand for VEGFR-1 and VEGFR-2 has also
been demonstrated to be expressed by high amounts (Zietz et al., 1998).
 For surgical pathologists, vascular invasion is an important prognostic factor
in malignant disease. In addition, the examination of vessels invaded by tumors is
essential for the study of the metastasis of malignant cells and the origin of tumors
(Welch and Rinker-Schaeffer, 1999). Importantly, lymphatic invasion seems to be of
greater prognostic importance for the survival of patients than blood vessel invasion
(Lauria et al., 1995). In general, markers of metastasis fall into two categories: the
first category predicts the metastatic propensity based on expression and/or activity of
a molecule with an established role in metastasis. The second category includes
markers for which there is no established mechanistic association with metastasis.
Each of these categories can be further divided on the basis of whether the amount of
marker, increases or decreases. This criterion impacts upon the clinical utility of the
marker. Certainly VEGFR-3 needs to be classified in the first category as it is likely
to correlate with a metastatic tendency.
In summary, we immunohistochemically demonstrated unexpected, widespread
VEGFR-3-expression in the majority of benign and malignant human vascular
tumors.  The expression of this marker is less consistent in malignant epithelioid
vascular tumors.  Because VEGFR-3 is absent in non-endothelial malignancies and
positive in most angiosarcomas, this marker is a useful adjunct in the
immunohistochemical identification of human endothelial cell neoplasms. In
particular, this antibody could serve to distinguish various fibrovascular proliferations
(e.g., stasis changes, chronic ulcers with surrounding reactive fibrosis) from difficult
cases of KS.
5. VEGF-C and VEGF-D expression in neuroendocrine cells and their
receptor, VEGFR-3 in fenestrated blood vessels in human tissues (Study V)
In the last study we wanted to complete VEGFR-3 expression studies after be-
coming suspicious due to unexpectedly broad distribution of the antigen in pathologi-
cal vasculature. The availability of novel antibodies against the ligands, VEGF-C and
VEGF-D at the same time made it possible to analyze if the receptor and its ligands
co-operate in the immediate vicinity of each other.
Even though the lymphatic system develops from large central veins in the embry-
onic jugular, retroperitoneal and perimesonephric regions surprisingly few adult tis-
sues retained VEGFR-3 expression in their venous endothelia (Dumont et al., 1998;
Sabin, 1909). Such endothelia were seen in the vessels of the cartilage channels in
vertebral bodies, in venous canals of the adrenal medulla and in the splenic venous
sinuses.
The capillary endothelia vary structurally according to their location and functions;
the major groups include continuous and discontinuous endothelia (Fig.4).
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Continuous endothelium is present in tissues such as connective tissue, lung and
brain, whereas discontinuous endothelium is typical of tissues undergoing high
molecular exchange across the vessel wall, such as secretion of hormones from
endocrine glands and filtration in glomeruli and in the choroid plexus. Electron
microscopic studies have established that for example the capillaries of the anterior
pituitary and glomerulus are fenestrated (Ross et al., 1995). In this study, we found
differences in VEGFR-3 expression between continuous and discontinuous
endothelia, the former typically being negative and the latter positive. This finding
suggests that VEGFR-3 plays a role in the transport functions of the discontinuous
and more permeable endothelia in locations such as in the endocrine organs and
kidney glomeruli.
Non-endothelial expression of VEGFR-3 was apparent in notochordal cells of 5
wk old embryos in accordance with earlier observations from avian embryos (Wilting
et al., 1997). This  data indicates completely different type of role for the receptor
from the present. Cytotrophoblast layer and intermediary trophoblasts gave positive
staining reaction in the first and second trimester placenta, but not in term placenta.
Indeed, VEGFR-3 is no longer needed for maintaining the integrity of endothelial cell
lining in a term placenta. Cytotrophoblasts, lining blood containing placental spaces,
are related to endothelial cells. A study with a commercial antibody against VEGFR-3
showed different results from ours (Vuorela et al., 2000). Among placentas from both
miscarriages and healthy controls the antigen was found faintly in cytotrophoblasts of
“missed abortion” pregnancy tissue. Stromal cells in placental villi and decidua
expressed the receptor constantly in both of the groups. In addition, vWF negative
structure resembling a blood vessel displayed some positivity. Recently, it has
become clear that invading cytotrophoblasts transform their receptor phenotype to
resemble the endothelial cells they replace (Damsky and Fisher, 1998). Interestingly,
we found that the cytotrophoblasts were stained for both VEGFR-3 and VEGF-C. It is
as yet unknown if VEGF-C is produced in these cells or just adsorbed to its receptor
on their surface.
A close association for VEGFR-3 and for its ligands, VEGF-C and VEGF-D was
found in the endocrine organs. However, we could not show a positive result for
VEGFR-3 in the capillaries in close proximity of VEGF-C/VEGF-D positive NE
cells. We concluded that if these growth factors have a function in the fenestrated ves-
sels, they must act via VEGFR-2. The distribution of VEGF-C and VEGF-D in the
normal tissues was, surprisingly, limited and in accordance with earlier RNA expres-
sion data.
After finding the association of VEGF-C and VEGF-D with NE cells it is
reasonable to hypothesize that these growth factors might contribute to tumorgenesis
of NE cells. NE cells have histologically common features represented by
argyrophilic cytoplasm containing NE granules. In particular, carcinoid tumors are
rare tumors that are thought to arise from NE cells (Caplin et al., 1998). They may be
found anywhere in the human body, but are traditionally described as originating from
the foregut, midgut, or hindgut. We proceeded to analyse carcinoid tumor material
from the gastrointestinal tract, and found both VEGF-C and VEGF-D positivity from
well-differentiated tumors (unpublished data of Taina A. Partanen, Johanna Arola and
Kari Alitalo). VEGF-C was distributed palisade-like in the tumor cells lining the edge
of the tumor. The strongest staining intensity could be seen in the smooth muscles
invading cell clusters. These data indicate that at least in some malignant tumors, the
tumor cells retain their cell specific expression pattern of VEGF-C. How such tumors
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overexpressing VEGF-C differ in terms of lymphatic metastasis will be interesting to
know.
VEGFR-3 was also expressed at major sites of hematopoiesis or blood cell
trafficking, such as in the sinusoids of the liver, spleen and bone marrow. The endo-
thelium at these sites is capable of regulating the translocation of hematopoietic cells,
which may be related to the function of VEGFR-3 in these locations.
In a relatively short time four distinct markers for lymphatic endothelium have
been characterized. These include VEGFR-3, podoplanin, Prox1 and LYVE-1
(Banerji et al., 1999; Breiteneder-Geleff et al., 1997; Jussila et al., 1998; Wigle and
Oliver, 1999). Podoplanin has been localized also to podocytes, parietal epithelial
cells of Bowman’s capsule, lung, choroid plexus, leptomeninges, osteocytes and os-
teoblasts (Breiteneder-Geleff et al., 1997). Podoplanin and VEGFR-3 antigens were
found to overlap in lymphatic endothelium, benign vascular tumors, and in angiosar-
comas [Breiteneder-Geleff, 1997 #37]. At least during development, Prox1 is also ex-
pressed in the lens, heart, liver, pancreas and in the central nervous system (Wigle and
Oliver, 1999). Our unpublished results have also demonstrated differences between
the distributions of the VEGFR-3 and LYVE-1 markers and it is as yet unknown how
useful these antigens would be for the detection of lymphatic vessels in e.g. malignant
processes. Antibodies against LYVE-1 demonstrate that the receptor seem to posses a
more prominent localization in lymphatic endothelium compared to that of VEGFR-3
which makes it easier to detect from a histological section. Further, preliminary data
shows that the tumoral neovasculature lacks it that is an advantage when analyzing
lymphatic vessels.
The ligands for VEGFR-3, VEGF-C and VEGF-D showed a narrow tissue
distribution. Results obtained from the frozen tissue sections where smooth muscle
cells and occasionally endothelial cells were stained with antibodies against these
ligands suggest paracrine functions for these growth factors in e.g. the arterial wall.
The high level of expression of VEGF-C in NE cells of respiratory and especially of
digestive mucosas and endocrine organs lined by fenestrated endothelial cells sug-
gests that it could play a role in the interaction between the NE cells and capillary en-
dothelia and perhaps in hormone secretion. Alternatively, VEGF-C and VEGF-D may
have roles unrelated to the vasculature in the NE system. Previously, VEGF has been
located in the NE cells in the prostatic vermontanum epithelia (Guy et al., 1998) and
in the digestive mucosa (Terris et al., 1998). Interestingly, VEGF and VEGF-C,
which are both potent vascular permeability factors, were partly colocalized in the
anterior pituitary gland. Although most of the VEGF-C positive cells were prolactin
producing, such cells may also include the follicular stellate cells of the pituitary
gland.
In conclusion, we have evaluated the distribution of VEGFR-3 and its ligands,
VEGF-C and VEGF-D in human fetal and adult tissues. Although our results confirm
the consistent presence of this receptor in lymphatic endothelia, they also reveal its
expression in discontinuous capillary endothelia, and production of its two ligands by
several types of NE cells. These data suggest that VEGFR-3 signals participate in the
maintenance on filtration or secretion functions across fenestrated capillary
endothelia.
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CONCLUSIONS
Anti-VEGFR-3 antibodies are useful tools in detecting lymphatic vessels in normal
skin as well as in other human tissues. However, VEGFR-3 is upregulated in the
tumor neovasculature which poses a limitation when identifying and counting
lymphatic vessels and “hot spots” (endothelial-stained vessels in clusters). VEGFR-3
expression in tumor vessels reflects the immature nature of tumor vascular
endothelium.
VEGFR-3 is widely distributed in vascular tumors, in both benign and malignant –
thus it does not correlate with tumor malignancy.
VEGFR-3 and podoplanin colocalize specifically on lymphatic endothelia and they
are associated with the tumor cells of all stages of AIDS-associated and classic KS.
Our results also demonstrate differential expression of the endothelial growth
factor receptors in distinct types of vessels in the human heart. This information is
useful for the understanding of their roles in physiological and pathological processes
and for their diagnostic and therapeutic application in cardiovascular medicine.
Expression of VEGF-C and VEGF-D is associated mainly with neuro-endocrine
and smooth muscle cells in adult tissues. Their receptor also appears in some
fenetrated blood vessel endothelia. Paracrine functions for VEGF-C and VEGF-D are
suggested by the studies where arterial wall smooth muscle cells and endothelial cells
were shown to stain for both of ligands. In the endocrine glands these growth factors
may contribute to the secretion of hormones into the circulation.
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